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Mikhail Chtcherbinine 
 
KINETIC AND STRUCTURAL CHARACTERIZATION OF ISOENZYME-SELECTIVE  
ALDEHYDE DEHYDROGENASE 1A INHIBITORS 
 
The human aldehyde dehydrogenase superfamily consists of 19 distinct genetic loci that 
play key roles in both health and disease. Aldehyde dehydrogenases are primarily involved in 
the metabolism of reactive aldehyde substrates; the ALDH1A subfamily, in particular, 
metabolizes retinaldehyde and is involved in a pathway regulating tissue differentiation, cell 
proliferation, and apoptosis. Recently, ALDH1 isoenzymes have been implicated as significant 
elements in cancer progression. ALDH1 activity has been used as a marker of cancer stem cells, a 
subpopulation of cancer stem cells with high drug resistance, proliferative potential, and ability 
to differentiate into multiple cell types.  In accordance with this, ALDH1 activity and expression 
has been shown to correlate with lower survival, increased chemoresistance, and increased 
chance of relapse in multiple solid cancer types, including breast, ovarian, lung, and colorectal. 
Despite the clear relevance of ALDH1 enzymes in cancer, the specific roles of individual 
isoenzymes are unclear. Isoenzyme-selective small molecule modulators of the ALDH1A 
subfamily would allow the probing of the function of individual isoenzymes in healthy and 
disease states. 
Two ALDH1A1 inhibitors, CM38 and C10, were previously identified in a high-throughput 
screen. In this study, CM38, an ALDH1A1-selective inhibitor, and CM10, an ALDH1A inhibitor, 
were characterized using kinetic assays, structural biology, and cell culture experiments. A 
structure-activity relationship was built for each series, and an X-ray crystallography structure 
was used to determine the binding mode. These approaches allowed the investigation of the 
ALDH1A active site and identification of structural features that can be used to design and 
improve selective modulators of this subfamily. CM38 and CM10 were also tested in a breast 
cancer cell line to determine their efficacy in a cellular environment. While the CM38 series 
showed warning signs of potential off-target toxicity, members of the CM10 compound series 
showed excellent initial characteristics as potential chemical tools. The results of this study may 
be useful in the design of new chemical tools to delineate the functions of individual ALDH1 
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isoenzymes in cancer biology, as well as in the development of drugs to selectively target cancer 
stem cells.   
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I. Introduction 
A. Aldehydes  
Aldehydes are a commonly occurring class of organic compounds characterized by the –
CHO chemical group (Figure 1A), and involved in an array of biological processes, from DNA 
damage to cell signalling. Aldehydes can originate from both exogenous and endogenous 
sources. A common exogenous source is the photochemical oxidation of hydrocarbons, which 
are either naturally present in the atmosphere or generated by vehicle exhaust (1). Vehicle 
exhaust is also responsible for the direct emission of aldehydes, such as formaldehyde, 
acetaldehyde, and acrolein. Non-automobile sources of aldehyde production can also include 
industrial emissions, forest fires, and coal-based power plants. Human exposure to aldehydes is 
not limited to atmospheric pollution; aldehydes are also present in food, drugs, and used 
substances.  Acetaldehyde is commonly produced by ethanol metabolism (2). Cigarette smoke 
contains numerous aldehydes, including acrolein, 4-hydroxynonenal (4-HNE), formaldehyde, and 
acetaldehyde, that may contribute to lung disease (3). Some drugs are aldehydes or are 
metabolically converted to them. An example is cyclophosphamide, an anticancer drug used in 
the treatment of leukemia, breast, and lung cancers (4). Metabolites of cyclophosphamide 
include aldehydes such as aldophosphamide and acrolein, and this metabolic conversion is 
necessary for the drug’s anticancer effect (4, 5).  
Aldehydes can also originate from a multitude of biological processes. Lipid 
peroxidation, a process linked to oxidative stress, produces aldehydes such as 4-hydroxynonenal 
(4-HNE) and malondialdehyde (MDA), among other bioactive products (1, 6). Glyceraldehyde-3-
phosphate is an intermediate in glycolysis, and can be further enzymatically converted to 
methylglyoxal (7). Retinaldehyde is a signalling intermediate that plays a key role in the retinoic 
acid pathway responsible for the regulation differentiation, development, and apoptosis (8).  
Although aldehydes can play important roles in biological processes, the total aldehyde 
burden must be carefully managed due to their bioactive and potentially toxic nature. In 
contrast to reactive oxygen species, aldehydes are longer lived and can interact with cellular 
components far from their origin (9). Aldehydes can be reactive toward both nucleic acids and 
proteins. In the case of nucleic acids, aldehydes can form DNA adducts and cause mutations.  
For example, acetaldehyde can form adducts to deoxyguanosine, while MDA can form adducts 
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to deoxyguanosine, deoxyadenosine, and deoxycytidine (10, 11). Through direct damage of the 
genome, aldehydes can increase mutation rate and may contribute to cancer development. 
Aldehydes can also cause carbonylation of proteins. Carbonylation is a type of oxidative damage 
that can lead to loss of function, protein cross-linking or formation of aggregates. Furthermore, 
heavy carbonylation can lead to toxicity and contribute to cardiovascular or neurodegenerative 
diseases (1, 12).  
 
Figure 1: Chemical Structures of Aldehydes 
A) General formula of aldehydes B) Acetaldehyde C) Formaldehyde D) Acrolein E) 4-
hydroxynonenal F) Retinaldehyde 
 
To control the biological levels of aldehydes, a range of enzymes are capable of 
metabolizing them. Broadly speaking, aldehydes can be oxidized to carboxylic acids, reduced to 
alcohols, or conjugated to glutathione (Figure 2) (1, 13). Oxidation is performed mainly by 
aldehyde dehydrogenases and cytochrome P450s. Aldehyde dehydrogenases are a superfamily 
of enzymes that are responsible for the irreversible, NAD(P)-dependent oxidation of aldehydes 
to carboxylic acids (9). Cytochrome P450s are a large family of heme thiolate enzymes 
responsible for the metabolism of a wide range of chemicals, including toxic ones like aldehydes 
(14). Aldehydes can also be reduced, which involves conversion to an alcohol that is mainly 
catalyzed by alpha-keto reductases and alcohol dehydrogenases. Alpha-keto reductases are a 
superfamily of over one hundred enzymes that generally catalyze carbonyl reduction reactions 
(13). Alcohol dehydrogenases are a group of enzymes with broad substrate specificity that can 
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facilitate the interconversion between alcohols and aldehydes; although the reactions are 
reversible, alcohol dehydrogenases are mainly known to catalyze the oxidation of alcohols to 
aldehydes as part of alcohol metabolism (15). Aldehydes can also be conjugated to glutathione 
by Glutathione-S-Transferases to allow excretion as mercapturic acid conjugates (13).  
Aldehydes are ubiquitous organic compounds that can function as part of normal 
biological processes or cause toxicity via DNA and protein damage. Aldehyde dehydrogenases 
are one of the key groups of enzymes that modulate aldehyde levels to regulate aldehyde-
associated biological pathways and reduce the toxic aldehyde burden.  
 
Figure 2: Primary Pathways of Aldehyde Metabolism 
Potential routes of 4-HNE Metabolism are shown as an example. A) Oxidation by aldehyde 
dehydrogenase B) Reduction by Aldo-Keto Reductase C) Glutathione conjugation by 
Glutathione-S-Transferase 
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Figure 3: The Phylogenetic Tree of the 19 Currently Known Human Aldehyde Dehydrogenase 
Enzymes 
 
B. Aldehyde Dehydrogenase Superfamily 
The human Aldehyde Dehydrogenase superfamily consists of at least 19 genetic loci, the 
isoenzymes produced from which can vary in substrate specificity, subcellular localization, and 
tissue-specific expression (Figure 3) (9, 16). The current nomenclature system for the ALDH 
superfamily, established in 1998, states that the “ALDH” is the root symbol, the next Arabic 
numeral identifies the family, followed by a letter to identify the subfamily, and, lastly, another 
Arabic numeral to identify the gene (17). Proteins in the same family are defined as having >40% 
sequence identity, while members of the same subfamily exhibit >60% sequence identity. The 
aldehyde dehydrogenases are mainly responsible for the oxidation of both aliphatic and 
aromatic aldehydes to their respective carboxylic acids. The NAD(P)+-dependent reaction 
mechanism for aldehyde oxidation is shared by all catalytic ALDH enzymes and occurs in five 
steps (Figure 4) (18). In the first step, the catalytic residue (Cys302 in mature ALDH2) is activated 
by water-mediated proton abstraction with the help of a glutamate (Glu268 in ALDH2). The 
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activated cysteine then performs a nucleophilic attack on the carbonyl carbon of the substrate 
aldehyde. A thiohemiacetal intermediate is formed, followed by hydride transfer to the NAD(P)+ 
cofactor. The basic Glutamate activates a water molecule, allowing it to perform a nucleophilic 
attack on the thioester-enzyme complex. A second tetrahedral intermediate forms and then 
rearranges to release the carboxylic acid and regenerate the activated Cysteine. The reaction 
releases the carboxylic acid product and the reduced cofactor NAD(P)H.  
 
 
Figure 4: Catalytic Mechanism of Aldehyde Oxidation by Aldehyde Dehydrogenase Enzymes 
Residue labeling based on ALDH2 
 
The shared catalytic function translates into structural similarities between the ALDH 
enzymes (Figure 5). Many known ALDH isoenzymes function as oligomers: either dimers or 
tetramers. Known ALDH structures show that the substrate and cofactor binding sites form a 
tunnel in order to allow both the aldehyde substrate and the NAD(P)+ cofactor access to the 
active cysteine residue from opposing sides of the tunnel.  
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Figure 5: Structural Features of Aldehyde Dehydrogenase Enzymes 
ALDH1A1 (PDB ID 4WJ9) is used to show some of the main structural features representative of 
most Aldehyde Dehydrogenases. A) The ALDH1A1 as a tetramer B) ALDH1A1 monomer unit C) 
The tetramerization domain of ALDH1A1, shown making intermolecular contacts with another 
subunit D) Substrate-binding pocket, with the catalytic cysteine highlighted in red E) Cofactor-
binding pocket 
 
Although their primary function is in aldehyde metabolism, aldehyde dehydrogenases 
can also fulfill other catalytic and non-catalytic roles. Several aldehyde dehydrogenase enzymes, 
namely ALDH1A1, ALDH1L1, ALDH1L2, ALDH2 and ALDH9A1, can also function as esterases and 
may play important roles in the bio activation of organic nitrites (19, 20). A small number of 
ALDH enzymes, such as ALDH1A1 and ALDH16A1, act as binding proteins for endogenous and 
exogenous compounds (19). Notably, ALDH16A1 lacks the catalytic cysteine, making it likely that 
it has no enzymatic activity and functions primarily as a binder of maspardin and/or other 
compounds (19, 21).  
Some members of the ALDH superfamily play critical roles in the function of the eye. 
ALDH enzymes act as crystallins, or proteins that allow for the transparency of the lens and 
cornea. In most mammals, ALDH3A1 is the primary corneal crystallin, while ALDH1A1 is a lens 
crystallin (22). ALDH3A1 and ALDH1A1 likely play structural roles in eye; however, they also 
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serve a highly important function in protecting the eye against UV damage. The isoenzymes can 
directly absorb UV radiation and detoxify UV-induced aldehydes (22). The two can also act as 
antioxidants, either directly by scavenging free aldehydes, or indirectly by producing NAD(P)H.  
C. ALDH1A Subfamily and the Retinoic Acid Pathway 
The ALDH1A subfamily consists of three isoenzymes: ALDH1A1, ALDH1A2, and 
ALDH1A3. The three share a unique function of catalyzing the oxidation of retinaldehyde as part 
of the retinoic acid pathway. The retinoic acid pathway plays a crucial role in the development 
of many organs and tissues, including those of the central nervous, cardiovascular, and 
respiratory systems (8, 23). It can also regulate cellular processes, such as proliferation, 
differentiation, and apoptosis (8). 
The retinoic acid pathway is initiated by retinol (Vitamin A) (Figure 6). Retinol cannot be 
synthesized by mammals, so it is instead absorbed from dietary carotenoids and retinyl esters 
(23). These compounds are processed into retinol, which is absorbed by mucosal cells, re-
esterified and stored as retinyl esters in the liver (24, 25).  From the liver, the retinyl esters are 
once again converted to retinol and circulated to the peripheral tissues while bound to retinol-
binding protein 4 (RBP4)(23). Retinol can diffuse into cells, but can also be transported by the 
RBP4 membrane receptor STRA6 (24, 26). Once in the cell, retinol is bound to the cellular 
retinol-binding protein 1 (RBP1) (23). Retinol is then converted to retinaldehyde (retinal) by 
retinol dehydrogenases (RDH) and alcohol dehydrogenases (ADH) (8). Retinal can, in turn, be 
converted to retinoic acid by members of the ALDH1A subfamily (8, 23).  Retinoic acid (RA) can 
bind to cellular retinoic acid binding protein (CRABP) and be shuttled to the nucleus; 
alternatively, it can be degraded to oxidized metabolites by CYP26 (8, 24). In the nucleus, RA can 
associate with retinoic acid receptors (RARs) and retinoic X receptors (RXRs)(27). RARs are 
activated by all-trans and 9-cis RA, while RXRs can only be activated by 9-cis RA. In the absence 
of ligands, these receptors form RAR/RXR heterodimers and recruit co-repressor proteins to RA 
response elements (RARE) (24). This results in the recruitment of histone deacetylases and 
transcriptional repression of RARE-containing genes. On the other hand, when RAR/RXR 
heterodimers are associated with retinoic acid ligands, they undergo a conformational change 
that causes them to recruit co-activating proteins (such as histone acetylates) and activate the 
target genes (28). Over 500 genes have been identified as potential targets of retinoic acid 
signalling, including genes involved in the retinoid pathway, such as RARA and CRABP2 (29). The 
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activation of retinoic acid transcriptional targets is generally thought to promote differentiation 
and apoptosis, while inhibiting cell proliferation (8). Consistent with this assumption, all-trans 
retinoic acid (ATRA) is used as a treatment in acute promyelocytic leukemia (30).  
In contrast to the established role of the RA pathway as an anti-cancer pathway, the 
therapeutic potential of ATRA has not been validated in solid tumors. (31). In fact, retinoic acids 
have shown negative results as a treatment in breast and lung cancers (31-33). This discrepancy 
between tumor types may be attributed, at least partially, to non-classical retinoic acid 
pathways (Figure 6).  Many of these pathways have effects that directly oppose those of their 
classical counterpart.  Ligand-bound RAR may be able to non-genomically activate the PI3K 
pathway (34). ATRA may be able to directly bind and inhibit protein kinase C (35). In terms of 
transcriptional modulation, RARs and RXRs can form heterodimers with other receptors, such as 
estrogen receptor α (ERα) and peroxisome proliferator-activated receptors (PPAR) (31). In these 
cases, RA can actually activate the transcriptional targets of ERα and PPAR, which can include 
pro-survival genes (31, 36). Through this mechanism, the RA pathway can activate the 
transcription of PDK-1, c-MYC, and cyclin D, all of which may potentially lead to cancer 
progression (31, 36).  
The retinoic acid pathway can promote seemingly opposing cellular responses, from 
differentiation and apoptosis to survival and proliferation. The exact outcome of RA signalling 
likely depends on the cell and tissue in which it occurs. As a result, while activation of retinoic 
acid signalling is an effective treatment in some cancer types, inhibition may yet prove a 
compelling therapeutic approach in other, distinct tumor types.  
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Figure 6: Retinoic Acid Signalling Pathway 
Highlighted are the classical and non-classical components of retinoid signalling. Classical RA 
pathways promote differentiation and apoptosis, while inhibiting cell proliferation. Non-classical 
pathways generally promote survival and cell growth.  
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Table 1: Human ALDH1A, ALDH2 and ALDH1B1 Isoenzymes  
Adapted from ALDH.org, Koppaka V. et al (2012) and Tomita H. et al (2016) (37-39) 
 
Isoenzyme 
Gene 
Locus 
Sequence 
Identity 
to 
ALDH1A1 
Molecular 
weight 
(kDa) 
Oligomer Tissue Expression 
Subcellular 
localization 
Known Substrate(s) 
PDB 
Structure ID 
ALDH1A1 9q21.13 100% 54.9 tetramer 
Liver, kidney, red 
blood cells, skeletal 
muscle, lung, breast, 
lens, stomach, brain, 
pancreas, testis, 
prostate, ovary 
Cytosol 
Retinal, 
acetaldehyde, 
aldophosphamide, 
lipid-peroxidation 
derived aldehydes, 
DOPAL 
4WJ9  
(human, apo-
enzyme) 
4WB9 
(human, 
complex with 
NADH) 
ALDH1A2 15q22.1 73.2% 56.7 tetramer 
Testis, liver, kidney, 
lung, brain 
Cytosol 
Retinal, lipid-
peroxidation 
derived aldehydes 
4X2Q 
(human, 
complex with 
NAD) 
ALDH1A3 15q26.3 70.9% 56.1 tetramer 
Kidney, skeletal 
muscle, lung, breast, 
stomach, salivary 
glands 
Cytosol 
Retinal, lipid-
peroxidation 
derived aldehydes 
N/A 
ALDH1B1 9p11.1 64.7% 57.3 tetramer 
Liver, kidney, heart, 
skeletal muscle, brain, 
prostate, lung, testes, 
placenta 
Mitochondria 
Lipid-peroxidation 
derived aldehydes, 
acetaldehyde 
N/A 
ALDH2 12q24.2 68.1% 56.4 tetramer 
Liver, kidney, heart, 
skeletal muscle, lens, 
brain, pancreas, 
prostate, spleen 
Mitochondria Acetaldehyde 
1O04 
(Human, 
complex with 
NAD) 
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D. ALDH1A1 
ALDH1A1 is a cytosolic homotetramer with broad tissue expression; it is near-ubiquitous 
in adult human organs, including brain, eyes, testes, kidneys, liver, and lungs (38). It is a well-
conserved protein, showing at least 90% amino acid sequence identity in mammals. Because of 
its high affinity for both all-trans- and 9-cis-retinaldehyde and its high expression in adult 
tissues, it is considered the predominant retinaldehyde-metabolizing enzyme in adults (37, 38). 
Its catalytic role extends to other substrates, such as acetaldehyde, a major intermediate in 
ethanol metabolism. ALDH1A1 executes a role as a detoxification enzyme by eliminating 
reactive aldehydes such as 4-HNE and MDA; however, these substrates can also inhibit the 
enzyme (40). ALDH1A1, along with ALDH3A1, can confer resistance to the anti-cancer drug 
cyclophosphamide by metabolizing its active aldehyde intermediates (41). As mentioned 
previously, ALDH1A1 is very important in the lens of the eye, as it plays both a structural role as 
a crystallin and a protective role by minimizing UV-induced oxidative damage (22). It has an 
additional non-catalytic role as a compound-binding protein. ALDH1A1 can bind androgen, 
thyroid, and cholesterol, though the significance of this function is unknown (40).   
One of the most pathology-relevant functions of ALDH1A1 is the role of the enzyme in 
midbrain catecholamine (dopamine) neurons. In brain dopaminergic neurons, ALDH1A1 
functions as part of a pathway to synthesize and co-release GABA, a key neurotransmitter in the 
mammalian central nervous system (42). ALDH1A1 also catalyzes the conversion of 3,4-
dihydroxyphenylacetaldehyde (DOPAL), a dopamine metabolite, to 3,4-Dihydroxyphenylacetic 
acid (DOPAC) (43). DOPAL is toxic and is thought to be at least partially responsible for the death 
of dopaminergic neurons in the striatum (43). The death of these cells is thought to be the cause 
of nigral depigmentation in the midbrain—one of the primary characteristics of Parkinson’s 
disease. Thus, ALDH1A1 has a key link to the pathogenesis of one of the most clinically 
significant neurodegenerative diseases. Consistent with this link, the DOPAC:DOPAL ratio is 
lowered both in the striatum of ALDH1A1,2 knockout mice and in the putamen of PD patients 
(44). This evidence suggests that reduced ALDH1A1 activity (such as through inhibition by 4-HNE 
and MDA) may contribute to the pathogenesis of Parkinson’s disease.  
The role of ALDH1A1 in mammals has been studied with knockout mouse models. As 
expected based on the protective role of ALDH1A1 in the eye, ALDH1A1(-/-) mice develop 
cataracts with age (45). Notably, however, the ALDH1A1(-/-) mice are also resistant to weight 
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gain from a high-fat diet and have reduced adipogenesis (46). Furthermore, ALDH1A1 has also 
been shown to regulate fat plasticity and the balance between white adipose tissue, which is 
linked to obesity, and brown adipose tissue, which is linked to leanness (47). ALDH1A1 is mainly 
expressed in white adipose tissue, and deficiency of ALDH1A1 promotes a thermogenic program 
in these cells (47). Aside from altered fat metabolism, ALDH1A1(-/-) mice also have reduced 
hepatic gluconeogenesis, decreased fasting glucose levels, and increased fatty acid oxidation 
(48). In accordance with this, model diabetic rats present increased hepatic expression of 
ALDH1A1 (49).  Together, these results indicate that the retinoid pathway and ALDH1A1 are key 
regulators of both fat and glucose metabolism, implicating ALDH1A1 as a potential therapeutic 
target in obesity and diabetes.  
E. ALDH1A2 
ALDH1A2 is a cytosolic homotetramer that is expressed in the testes, liver, kidney, lung, 
and brain (9). ALDH1A2 has high selectivity for all-trans retinaldehyde over its other substrates 
(50). Like ALDH1A1, its secondary substrates include lipid peroxidation products like decanal and 
octanal, allowing it to also serve as a detoxifying enzyme (50).  
Animal models suggest that ALDH1A2 plays a key role in the early development of 
several organs. ALDH1A2 (-/-) mouse models die in embryogenesis due to impaired 
morphogenesis of the heart (51). When rescued through supplementation with RA, the mice still 
show defects in the development of the branchial arches, hindbrain neural patterning and the 
enteric nervous system (51). ALDH1A2 has also been implicated in the development of the 
retina, forebrain, and pancreas (52-54). As an extension of its role in development, ALDH1A2 
also facilitates tissue regeneration in some species. ALDH1A2 was shown to be upregulated 
following fin or heart injury in zebrafish, and ALDH1A2-catalyzed production of RA was 
demonstrated to be necessary for regeneration (55, 56).  
F. ALDH1A3 
ALDH1A3 is a cytosolic tetramer expressed in stomach, breast, kidney, and lung tissues, 
among others (9). Like ALDH1A2, it is preferential for all-trans retinaldehyde, but can also 
oxidize 9-cis retinaldehyde, octanal, and decanal (9, 57).  
ALDH1A3 (-/-) mice die at birth due a blockage of the nasal passage; however, unlike 
ALDH1A2 knockouts, the mice show no obvious deformities or health concerns until birth (58, 
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59). The mice can be rescued by treatment with retinoic acid, suggesting that the primary 
function of ALDH1A3 in development is tissue-specific retinoic acid production (58). Knockout 
models have also implicated ALDH1A3 in the development of the eye, forebrain, and kidneys 
(60-62). In the development of the eye, ALDH1A3 and ALDH1A1 are thought to have overlapping 
roles, as ALDH1A1(-/-) ALDH1A3(-/-) double knockout mice demonstrated exacerbated defects 
compared to either single knockout (60, 63) .  
G. Cancer Stem Cells 
A growing paradigm in cancer research is the theory of cancer stem cells (CSCs), or a 
subpopulation of stem-like cells that fulfill a critical role in tumor development. The basic 
properties of cancer stem cells include cell renewal, ability to differentiate into multiple cell 
types, extensive proliferative potential, and resistance to classical chemotherapy and 
radiotherapy (64, 65). Cancer stem cells can be identified by surface cell markers, which vary 
with tumor type. Commonly used markers include CD24, CD44, and CD133 (65). Other 
properties, such as sphere-forming capacity or ALDH1 activity, can also be used as markers (65). 
ALDH1 enzymatic activity stands out as a universal marker in CSCs and progenitor cells across a 
multitude of cell types; accordingly, this property been successfully employed to isolate CSCs 
from head and neck squamous cell carcinomas, as well as lung, prostate, pancreas, and breast 
cancers (66).  
Cancer stem cells are thought to be responsible for many of the properties that make 
cancers difficult to treat, such as drug resistance, quiescence following therapy, tumor 
recurrence, and metastasis (67). It is becoming increasingly apparent that many therapy options 
aiming to simply reduce the size of the tumor or target the most numerous cancer cell type do 
not effectively prevent recurrence or metastasis, as they do not affect CSCs (Figure 7) (67). 
Tumors are heterogeneous, and should be treated as such in order to develop effective and 
permanent cancer treatments. One possible approach would be to combine classical therapies 
with those that selectively target the cancer stem subpopulation.  
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Figure 7: The Cancer Stem Cell Model 
A) Asymmetric and symmetric cell division by CSCs leads to tumor growth B) CSCs are resistant 
to standard therapies, leading to tumor relapse C) Combinatorial therapies that target both the 
tumor bulk and the CSCs are a promising approach for complete elimination of the tumor 
 
A number of strategies are being developed to target cancer stem cells. Common 
approaches include targeting the cell surface markers, key signalling pathways, ABC 
transporters, and the tumor microenvironment (65, 68). Conjugated monoclonal antibodies are 
a popular method of targeting CSC surface markers like CD133, CD33, CD44, and CD47 (65, 68). 
One such method involved anti-CD133 antibody-conjugated nanoparticles loaded with the anti-
cancer agent paclitaxel. The strategy was effective in reducing the CSC population and inhibiting 
tumor growth (69). A number of signalling pathways have been identified as having a significant 
role in CSCs, including NF-κB, Notch, Hedgehog, PI3K/Akt, Wnt/b-catenin, JAK/STAT, and Hippo-
YAP/TAZ (65, 67, 68). Antibodies and small-molecule compounds that inhibit these pathways are 
being developed and tested, including modified combinatorial strategies of targeting multiple 
pathways at once (65, 70). Features of the microenvironment that help support CSCs, such as 
secreted factors, microvasculature, and weakly acidic pH, are also potentially exploitable in 
treatment (68). An example of a secreted factor is CXCL12, which activates the CXCR4 receptor 
in CSCs and promotes close contact to the tumor stroma, proliferation, survival, and invasion 
(71).  Plerixafor is a CXCR4 antagonist that was shown to promote mobilization of the stem cells 
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into blood and render them more vulnerable to drug therapy (72). ATP-binding cassette (ABC) 
transporters are efflux pumps that are thought to contribute to multi-drug resistance (73). A 
variety of ABC transporter inhibitors are currently being investigated as sensitizing agents to 
reduce the resistance to other drug types (65). Although ALDH1 enzymes are known to be 
markers of CSCs in many cancer types, they are relatively unexplored as drug targets to 
selectively eliminate CSCs.  
H. Aldefluor Assay 
Currently popular approaches for identifying cancer stem cells based on ALDH activity 
include the Aldefluor Assay and immunohistochemistry. The Aldefluor assay is a commercially 
available (StemCell Technologies, Vancouver, BC, Canada) assay that can measure the functional 
activity of ALDH in living cells (74, 75). Together with a fluorescence-activated cell sorter, the 
Aldefluor assay can be used to sort and isolate cells with high ALDH activity (ALDHbri cells) (74, 
76). The assay works by providing a fluorescent cell-permeable ALDH substrate BODIPY-
aminoacetaldehyde (BAAA), that can be converted to BODIPY-aminoacetate (BAA) by active 
ALDH enzymes (Figure 8) (75). BAA is not membrane-permeable, so it is retained by cells with 
active ALDH and labels them with a fluorescent signal (74, 75). DEAB is a ALDH inhibitor that is 
provided with the assay for use in a negative control (74). There are many advantages to the 
Aldefluor assay, as it is non-toxic and does not require UV light for excitation (75). However, the 
major disadvantage of the assay is that it is not isoenzyme-selective; neither the BAAA 
substrate, nor the DEAB inhibitor are specific for any one isoenzyme in the superfamily (38, 76, 
77). Although the Aldefluor signal is often attributed to ALDH1A1, it could also be produced by 
other isoenzymes, such as ALDH1A2 and ALDH1A3 (38, 76). Isoenzyme-selective assays and 
inhibitors are still sorely needed in order to delineate the functions of specific ALDH1 
isoenzymes in cancer biology.  
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Figure 8: Aldefluor Assay 
A) Structure of BODIPY-Aminoacetaldehyde (BAAA), the Aldefluor substrate B) Structure of 
BODIPY-Aminoacetate (BAA), the Aldefluor product C) In a cell with active ALDH, BAAA is 
converted to BAA, labeling the cell with a fluorescent signal D) In a cell without active ALDH, 
BAAA does not undergo conversion and is free to diffuse out of the cell E) In the negative 
control, the DEAB inhibitor prevents conversion of BAAA to BAA, thereby preventing the labeling 
of the cell 
 
I. ALDH1 Family in Breast Cancer 
The expression of the ALDH1 family has been suggested as a marker of breast cancer 
stem cells, and its impact on clinical prognosis has been thoroughly studied. A meta-analysis of 
15 publications on breast cancer patients revealed that high expression of ALDH1A1 (as 
determined by immunohistochemistry) correlated with a poor prognosis, as well as 
unfavourable tumor characteristics like larger tumor size, greater possibility of lymph node 
metastasis, higher HER2 expression, and lower expression of estrogen receptor (78). A further 
study of 653 breast carcinoma specimens largely corroborated these results, but also suggested 
that ALDH1 had a significant impact on the prognosis of luminal-type cancer but not triple-
negative or HER2-type (79). In the same paper, ALDH1 expression was shown to correlate to 
chemoresistance, even in triple-negative breast cancer (79). Furthermore, ALDH1 expression has 
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been suggested to be a good predictor of relapse, and the proportion of cells with high ALDH1 
expression was shown to increase after relapse (80).  These results are further reinforced by cell 
culture experiments, in which ALDHbri cells sorted by Aldefluor assay displayed higher invasive 
potential in matrigel assays, increased mammosphere-generation, and increased tumor 
initiation and metastasis development in mice (81, 82).  All these results are consistent with the 
use of ALDH1 expression as a cancer stem cell marker both in cell culture and in the clinic. 
While the characteristics of ALDH1-expressing cells are usually attributed to ALDH1A1, 
there is some evidence that ALDH1A3 also plays a significant role in this disease. It has been 
suggested that ALDH1A3 was primarily responsible for the ALDHbri signal in multiple breast cell 
lines, and was a better predictor of tumor progression and metastatic potential (83, 84). A study 
of 176 breast cancer specimens also suggested that ALDH1A3 expression had a more significant 
impact on survival than ALDH1A1 (84). 
Although there is a strong body of evidence supporting the prognostic value of ALDH1 in 
breast cancer, there are also a number of studies that refute this assessment. In a study of 321 
node-negative and 318 node-positive breast cancer patients, ALDH1 expression, as determined 
by Automated Quantitative Analysis (AQUA), was not found to significantly affect outcome (85). 
Another paper reported that in a study of 245 invasive cancer specimens, ALDH1 expression did 
not correlate with tumor size, tumor grade, lymphovascular invasion, or survival (86). In smaller 
cohorts of 45 and 40 triple-negative specimens, the study actually found that high stromal 
expression of ALDH1 correlated with increased disease-free survival (86).  
There are many possible explanations for the observed discrepancies in literature, 
including differences in cancer type, specific tissue (stromal vs. tumor), and detection method 
(Immunohistochemistry, Aldefluor assay, Automated Quantitative Analysis). Given that 
ALDH1A1 and ALDH1A3, as well as possibly other isoenzymes, may play a role, differences in the 
isoenzyme selectivity of antibodies used for immunohistochemistry could seriously sway results.  
Although the prognostic value of ALDH1 expression is still under debate, the idea that ALDH1 
expression is a marker of CSCs and an indicator of poor prognosis seems to currently have more 
supporting evidence (9, 38). 
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J. ALDH1 Family in Ovarian Cancer 
As in the case of breast cancer, the prognostic value of ALDH1 expression in ovarian 
cancer in controversial. In two studies of 84 and 100 ovarian cancer specimens, high ALDH1 
expression correlated with significantly worse survival (87, 88).  In a study of 55 matched 
samples taken before and after taxane/platinum-based therapy, ALDH1 expression was 
increased significantly (median change of three-fold) in non-regressing tumors (89). 
Furthermore, the presence of these ALDH1-high cell subpopulations increased the risk of death 
4.18 times, suggesting that ALDH1-high CSCs are responsible for both chemoresistance and a 
more aggressive phenotype (89). On the other hand, larger studies of 442 and 248 ovarian 
carcinoma patients found that high ALDH1 expression correlated with higher overall and 
disease-free survival (90, 91).  
Despite the questionable role of ALDH1 in clinical cases, ALDH1 expression has 
consistently been shown to correlate with stemness properties in cell culture experiments. 
ALDHbri cells of multiple ovarian cancer cell lines showed higher spheroid-forming ability, 
invasiveness, tumorigenic potential in mice, and chemoresistance (87, 92). Another study 
showed that ALDH1A1 was upregulated in spheroids compared to cells grown in monolayer and 
that the use of a ALDH1A1-selective inhibitor reduced spheroid formation (93).  
Overall, despite a strong correlation with stemness characteristic in the lab, the 
prognostic value of ALDH1 expression in ovarian cancer remains under question. As in breast 
cancer, the high variation between studies could be due to differences in cancer subtype, 
detection method, or the selectivity of the antibody used for immunohistochemistry. 
K. ALDH1 Family in Lung Cancer 
In lung cancer, high populations of ALDH1-expressing are generally thought to be 
associated with a worse prognosis. A meta-analysis of 14 publications comprising 1926 cases 
found that ALDH1 expression was correlated with lymph node metastasis, higher tumor stage, 
and decreased overall survival (94). Although the prognostic value of ALDH1 in lung cancer is 
generally accepted by the scientific community, it is not without challengers. For example, a 
study of two cohorts of 134 and 296 patients with non-small lung cancer found that the absence 
of ALDH1 expression (as determined by AQUA analysis) was correlated with a worse prognosis 
(95). 
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Evidence in cell culture experiments further confirms the idea that ALDH1 expression is 
a marker of cancer stem cells in lung cancer. ALDHbri cells have been found to have higher 
proliferation rates, colony formation ability, chemoresistance, and tumor-forming ability in nude 
mice (96, 97). The current consensus is that ALDH1 expression is an effective marker of cancer 
cell stemness in lung cancer, as supported by strong evidence in vitro and in the clinic.   
L. ALDH1 Family in Colorectal Cancer 
Colorectal cancer is another cancer type in which ALDH1 expression may have value as a 
cancer stem cell marker. A meta-analysis of 9 publications encompassing 1203 patient samples 
found that high ALDH1 expression was correlated with higher tumor stage and decreased 
disease-free and overall survival (98). On the other hand, a number of other studies have found 
the opposite result. A study of 1287 patient samples found no correlation between ALDH1 
expression and survival time (99). Another paper looking at 659 colon cancer samples and 338 
rectal cancer samples found no correlation between cytoplasmic ALDH1A1 expression and 
prognosis (100). However, the study did find that in a small subset of samples that showed 
nuclear expression of ALDH1A1, survival time was significantly reduced (100). This may hint at a 
yet-unexplored nuclear role of ALDH1A1 in colorectal cancer tumorigenesis.  
Despite the controversy in the clinical setting, ALDH1 expression still appears to be a 
marker of cancer stemness in cell culture. For example, ALDHbri cells were shown to have 
significantly higher tumor-initiating ability in nude mice (101). The prognostic value of ALDH1 
expression in colorectal cancer is still under debate and has no clear consensus. As before, 
variation in tumor subtype of experimental methods could be responsible for the high degree of 
disagreement observed on this topic.  
M. A Note on the Inconsistencies in Clinical Studies 
Across all the cancer types discussed, the use of ALDH1 expression as a prognostic factor 
in the clinic is somewhat controversial due to variability between different studies. At the same 
time, ALDH1 expression as measured by Aldefluor assay in cell culture experiments consistently 
correlates with stemness characteristics. One plausible explanation for the discrepancy is that 
cells in culture are inherently different from those in vivo. Another very likely explanation is the 
difference in experimental approach between the Aldefluor assay and immunohistochemistry. 
The Aldefluor assay is applied consistently across all studies, whereas different antibodies can 
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lead to a large variance between different immunohistochemistry experiments. Additionally, the 
Aldefluor assay measures activity rather than enzyme concentration. Furthermore, the Aldefluor 
assay provides a relatively non-selective substrate, thus allowing a number of isoenzymes to 
contribute to the signal. Since the identity of all ALDH isoenzymes that can contribute to 
stemness characteristics is not certain, the non-selective nature of the assay may be particularly 
important in some cancer types. An immunohistochemistry approach can lead to variability as 
different antibodies, or even antibody lots, can have different isoenzyme selectivities. Without 
rigorous testing, the relative contribution of any isoenzyme to an immunohistochemistry signal 
is both uncertain and inconsistent. More regularity in antibody use would likely improve the 
consistency of clinical studies. Ideally, an established protocol for antibody validation and 
verification of isoenzyme selectivity should be used for every antibody.  
N. Potential Functional Roles of ALDH1 Enzymes in Cancer 
Despite a strong body of evidence substantiating the role of the ALDH1 family in cancer 
progression, the mechanism of its involvement is largely unknown. Nevertheless, based on 
established properties of ALDH1 enzymes, some functions that are likely to contribute to cancer 
biology and stemness can be discerned.  
The ability of ALDH1A isoenzyme to produce retinoic acid is one such function. As 
discussed in detail earlier, ALDH1A1, ALDH1A2, and ALDH1A3 regulate the retinaldehyde 
oxidation step in the retinoic acid pathway. The retinoic acid pathway can feed into the classical 
and non-classical retinoid responses. In particular, the non-classical retinoic acid pathway can 
lead to activation of PI3K and upregulation of PDK1, c-MYC, and Cyclin D, all of which have 
known links to oncogenesis (Figure 6)(31). As such, depending on the relative expression of RAR, 
RXR, PPAR, and ERα receptors, increased activation of retinoic acid signalling may contribute to 
cancer progression in some cell types.  
ALDH1 enzymes have also been known to contribute to drug resistance, a key property 
of cancer stem cells. ALDH1A1 is known to oxidize the active metabolites of the anti-cancer drug 
cyclophosphamide and contribute to resistance (41). ALDH isoenzymes may also protect cells 
from the oxidative stress caused by radiotherapy or some anti-neoplastic agents (31).  ALDH1A1 
has also been proposed to contribute to drug resistance by regulating the cell cycle. An 
ALDH1A1 knockdown in ovarian cancer cells showed increased expression of KLF4 and 
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decreased expression of p21 (92). As a result, ALDH1A1-knockdown cells accumulated in the S 
and G2 phases of the cell cycle, which is likely to render them more vulnerable to therapy (92). 
ALDH1 enzymes may also contribute to the cancer stem cell phenotype by reducing the 
levels of reactive oxygen species (ROS). Cancer stem cells are known to have lower levels of ROS, 
and maintaining this low level is necessary for the CSC phenotype (102, 103). ALDH1 enzymes 
are known to be able to fulfill an antioxidant role by scavenging reactive aldehydes and 
producing NAD(P)H (22). Therefore, high ALDH1 expression may be necessary to protect CSCs 
from ROS-induced DNA damage and cell death.  
O. High-Throughput Esterase Screen for ALDH1A1-Selective Inhibitors 
A high throughput screen was previously conducted to identify selective modulators of 
ALDH1A1 (104). The screen was successful and achieved a Z-score of 0.67. After two rounds of 
screening, 256 modulators of ALDH1A1 were identified. After further testing, 30 compounds 
were found that selectively inhibited ALDH1A1 compared to ALDH2 and ALDH3A1. The screen 
showed that it was possible to develop isoenzyme-selective inhibitors by making use of the 
structural differences between ALDH active sites. The screen also provided a number of 
inhibitors that could act as lead compounds for further development of isoenzyme-selective 
inhibitors of the ALDH1A subfamily.  
P. Hypothesis and Approach 
Members of the ALDH1 family have a clear role in cancer pathogenesis. High expression 
of ALDH1 has been linked to cancer stem cell characteristics like high proliferation, invasiveness, 
chemoresistance, and metastatic potential. Some studies have also linked ALDH1 expression in 
tumors to poor prognosis in breast, ovarian, lung, and colorectal cancers, among others. Despite 
mounting evidence, the specific contribution of each isoenzyme in the family to cancer biology 
remains unknown. Furthermore, the complete mechanism of ALDH1 activity in cancer is equally 
obscure. Isoenzyme-selective inhibitors of the ALDH1 family would allow studies to delineate 
the roles of select ALDH1 isoenzymes in each cancer type. In addition, inhibitors would allow 
researchers to verify the importance of the ALDH1 enzymatic activity and retinoic acid 
production while keeping any additional activities unaffected.  
It was hypothesized that the ALDH1A1 inhibitors previously identified in the high-
throughput screen could be used as lead compounds to develop isoenzyme-selective inhibitors 
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of the ALDH1A subfamily. The development of these compounds would help map out useful 
structural features of the ALDH1A active site and aid the structure-based drug design targeting 
these enzymes in the future. These compounds would also have immediate use in the 
identification of the roles of ALDH1A1, ALDH1A2, and ALDH1A3 in cancer biology. Beyond that, 
these compounds could be used in drug development in order to target in cancer stem cells in 
the clinic. Additionally, due to the isoenzyme’s role in other diseases, ALDH1A1-selective 
modulators could be applied in the treatment of obesity, diabetes, and neurodegenerative 
disease.  
The approach utilized here consisted of kinetic measurements, structural biology, and 
cell culture experiments. A structure-activity relationship was developed for each hit compound 
by analyzing the selectivity and potency of each analogue in in vitro kinetic assays. The binding 
mode of select compounds was identified by using X-ray crystallography. Cell culture 
experiments were used to evaluate the ability of select compounds to impair the proliferation of 
a breast cancer cell line.  
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II. Materials and Methods 
A. Materials 
All chemical reagents used for protein purification, X-ray crystallography, and enzyme 
kinetics were purchased from Sigma Aldrich (St. Louis, MO), unless otherwise specified. All 
reagents used for propagation of and experiments involving mammalian cell lines were 
purchased from Corning Inc. (Corning, NY), unless otherwise specified. Small molecule 
compounds were purchased from ChemDiv Corporation (San Diego, CA) and ChemBridge 
Corporation (Chicago, IL).  
B. Methods 
All measurements for enzyme activity assays and cell viability assays were taken in 
triplicate unless stated otherwise.  
1. Purification of ALDH Isoenzymes 
Identical protocols were used for the purification of ALDH1A1, ALDH1A2, ALDH1A3, and 
ALDH2. Full cDNAs of ALDH isoenzymes, previously subcloned into the pT7-7 vector, were used 
to transform BL21 (DE3) cells. Transformed cells were plated on Agar plates with 100 µg/mL 
Ampicillin and grown overnight. A single colony was grown overnight in 20 mL TY buffer 
containing 100 µg/mL Ampicillin (TY-amp). The overnight culture was diluted to 100 mL with TY-
Amp and grown for 3 more hours. 10 mL of this starter culture was then added to each of 8 1 L 
cultures of TY-Amp and grown at 37 °C, with 200 rpm shaking, until an optical density of 0.6-0.8 
at 600 nm was reached. Expression of the ALDH enzyme was induced by the addition of IPTG 
(GoldBio, St. Louis, MO) to a concentration of 100 µM. Induction was conducted overnight at 16 
°C and 160 rpm. Cells were spun down at 5000 rpm, 10 min, 4 °C (Beckman Avanti J-25, JA-10 
Rotor), and growth medium was decanted. Cell pellets were flash-frozen in liquid nitrogen and 
stored at -80 °C. Frozen pellets were thawed slowly and suspended in cold lysis buffer (10 mM 
NaH2PO4, 2 mM EDTA, 1 mM benzamidine, 1 mM DTT, pH 7.0). All buffers used in enzyme 
purification were sparged with helium to reduce oxygen-dependent cysteine oxidation. DTT 
(GoldBio, St. Louis, MO) was added to buffers immediately before use. Cells were lysed by three 
consecutive passages through a microfluidizer (Microfluidics 110L). Lysate was pelletized by 
centrifugation at 35000 rpm, 45 min, 4 °C (Beckman Coulter Optima L-90K Ultracentrifuge, Ti-45 
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Rotor). The supernatant was dialyzed twice against 4 L of Lysis buffer at 4 °C, first for 4 hr and 
then overnight. The DEAE column was equilibrated with 100 mL of lysis buffer using the BioLogic 
LP chromatography system (BioRad, Hercules, CA). The clarified lysate was loaded and the 
column was washed to baseline with 300 mL of lysis buffer. Elution was performed by passing 
300 mL of 0-100 % elution buffer (lysis buffer with additional 250 mM NaCl) and collecting 6-8 
fractions. The presence and purity of the target enzyme in the collected fractions was examined 
by running samples on a 10 % SDS-PAGE gel and staining with Coomassie dye. Fractions 
containing the target enzyme were pooled for the next step. The 4-HAP affinity column was 
equilibrated with 120 mL of HAP buffer (20 mM NaH2PO4, 1 mM EDTA, 50 mM NaCl, 1 mM DTT, 
pH 7.5). The DEAE pool was loaded and the column washed to baseline with 200 mL of HAP 
buffer. Elution was performed with 100 mL of p-HAP elution buffer (10 mM p-HAP in HAP 
buffer). Elution was collected as one fraction and a BioRad protein assay (BioRad Laboratories, 
Hercules, CA), was used to observe the completion of protein elution. The HAP eluate was 
dialyzed three times against 4 L of storage buffer (10 mM Aces, 1 mM DTT, pH 6.6), with each 
dialysis being 4 hours to overnight at 4 °C. The protein was concentrated to 5-20 mg/mL using 
Amicon Ultra Centrifuge Devices (Millipore, Bedford, MA). Protein concentration was 
determined using the BioRad protein assay, and specific activity was determined by measuring 
the production of NADH (molar extinction coefficient of 6220 M-1 cm -1 ) in a solution containing 
200 µM propionaldehyde and 1.5 mM NAD+ on a spectrophotometer. The protein was then 
aliquoted, flash-frozen in liquid nitrogen and stored at -80 °C. ALDH1B1, ALDH1L1, ALDH3A1, 
ALDH4A1, and ALDH5A1 were purified as described previously (105-107). Some enzyme stocks 
used were purified and provided by Cameron Buchman, Dr. Cynthia Morgan, Lanmin Zhai, and 
Dr. Bibek Parajuli.  
2. Aldehyde Dehydrogenase Activity Assays 
The activity rates of aldehyde dehydrogenase isoenzymes and their inhibition by 
compounds were determined by a spectrophotometric assay, in which the production of NADH 
was measured at 340 nm (molar extinction coefficient of 6220 M-1 cm -1). (Figure 9).  
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Figure 9: Reaction Used to Measure Activity Rate of Aldehyde Dehydrogenase Enzymes 
For ALDH1A1, ALDH1A2, ALDH1A3, ALDH2, and ALDH1L1, 30 mM BES pH 7.5 was used as a 
buffer; for ALDH3A1, ALDH4A1, and ALDH5A1 100 mM NaH2PO4 pH 7.5 was used instead. 
Propionaldehyde was used as the substrate for all isoenzymes except ALDH3A1, for which 
benzaldehyde was used. Assay reagent concentrations were set up as listed in Table 2, in order 
to achieve saturation of NAD+ and substrate for each enzyme, but still allow measurement of the 
reaction at initial-rate conditions.  
 
Table 2: Aldehyde Dehydrogenase Activity Assay Reagent Concentrations 
Enzyme Used 
Concentration of 
NAD (µM) 
Concentration of 
substrate (µM) 
Concentration of 
Enzyme (nM) 
ALDH1A1 200 100 400 
ALDH1A2 200 100 200 
ALDH1A3 200 100 600 
ALDH2 200 100 100 
ALDH1B1 500 200 150 
ALDH3A1 300 300 20 
ALDH4A1 1500 20000 100 
ALDH5A1 1500 2000 100 
ALDH1L1 500 4000 200 
 
Enzyme was incubated with compound for 2 minutes before substrate was added to 
initiate the reaction. Assays were set up in 96-well flat-bottom plates and measured on a 
Spectramax 340PC plate reader (Molecular Devices, Sunnyvale, CA). Readings were taken every 
10 seconds for 5 minutes. Initially, all compounds were screened at 20 µM. All inhibition assays 
included 2 % DMSO with compound or DMSO alone as control. Activity was calculated as a ratio 
to control. 
𝑅𝑎𝑡𝑒 𝑟𝑎𝑡𝑖𝑜 𝑡𝑜 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 =
𝑅𝑎𝑡𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑟𝑒𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
𝑅𝑎𝑡𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑎𝑏𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
 
For the CM38 series, compounds were screened with ALDH1A1 first and those that 
inhibited more than 50 % were screened with ALDH1A2, ALDH1A3, ALDH2, and ALDH1B1. For 
the CM010 series, all compounds were screened with ALDH1A1, ALDH1A2, ALDH1A3, ALDH2, 
and ALDH1B1. IC50s were collected in cases where a compound inhibited an isoenzyme more 
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than 60 % compared to DMSO control. For IC50s, a range of concentrations composed of at least 
8 points was used. Measurements were fit to a four-parameter EC50 equation and graphed using 
SigmaPlot V12.3 (Systat, San Jose, CA).   
 
3. Steady-State Kinetics 
Steady-state kinetics were performed in order to find the mode of inhibition of the 
compounds. In order to determine the appropriate reaction parameters, Km values were 
experimentally derived for ALDH1A1 with respect to acetaldehyde and NAD+. To determine the 
Km with respect to acetaldehyde, an activity assay was set up with 200 µM ALDH1A1 and a 
saturating NAD+ concentration of 1 mM, while varying the concentration of acetaldehyde from 1 
µM to 1 mM.  Similarly, to determine the Km with respect to NAD+, an assay was set up with 200 
µM ALDH1A1 and a saturating acetaldehyde concentration of 500 mM, while varying the 
concentration of NAD+ from 5 µM to 1 mM.  Reactions were initiated with the addition of 
substrate and activity was measured at 340 nm on a Cary 50-Bio UV-Visible Spectrophotometer 
(Agilent, Santa Clara, CA) using 10 second intervals for 2 minutes. Results were modeled and 
graphed using the single-substrate substrate inhibition module of SigmaPlot V12.3. The Km 
values were found to be 40 ±6.4 µM with respect to acetaldehyde and 99 ±11 µM with respect 
to NAD+ (Figure 10). Substrate inhibition was also observed, with ALDH1A1 having a Ki of 2.0 ± 
0.56 mM with respect to acetaldehyde and 2.9 ± 0.73 mM with respect to NAD+.  
 
Figure 10: Km Measurement of ALDH1A1 with Respect to A) Acetaldehyde and B) NAD+ 
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To find the mode of inhibition with respect to NAD+, an activity assay was set up with 
150-200 nM ALDH1A1 and 1 mM propionaldehyde while varying the concentration of NAD+ 
from 20 µM to 200 µM. Likewise, to find the mode of inhibition with respect to acetaldehyde, an 
activity assay was set up with 150-200 nM ALDH1A1 and 1 mM NAD+ while varying the 
concentration of acetaldehyde from 20 µM to 200 µM. Concentration of inhibitor was varied at 
four concentrations in a range around the approximate Ki. Reactions were initiated by the 
addition of substrate, and activity was measured at 340 nm on a Cary 50-Bio UV-Visible 
Spectrophotometer. Readings were taken every 10 seconds for 2 minutes. Results were 
modeled and graphed using the tight-binding inhibition and single substrate—single inhibitor 
modules of SigmaPlot V12.3.  
 
4. X-ray Crystallography 
All protein used for crystallography was stored at -20 °C in 50 % (v/v) glycerol. Before 
use, it was dialyzed 3 times against 4 L of 10 mM Aces, 1 mM DTT, pH 6.6 buffer at 4°C. Each 
dialysis was at least 4 hours in length. All solutions used for setup of crystals were filtered using 
a 0.22 µm membrane. Crystal conditions were set up using the sitting drop method in 24-well 
Cryschem plates (Hampton Research, Laguna, CA), by combining 3 µL of protein stock (3-4 
mg/mL) with 3 µL of crystallization solution over 500 µL of reservoir solution. Drops were mixed 
by pipetting. Crystallization solutions of 100 mM BisTris pH 6.1-6.4, 9-11 % PEG3350 (Hampton 
Research, Laguna, CA), 200 mM NaCl, and 5 mM YbCl3 were used. The crystal plates were 
incubated at 20 °C. Crystal formation was observed within 3-20 days. The complex with CM38 
was made by soaking the crystal with 500 µM compound in 2 % DMSO and 1 mM NAD+ for 5 
hours. The co-crystal with 3988-0485 was made by adding 250 uM of compound and 2 % DMSO 
to the crystallization solution. The freezing condition was composed of 20 % ethylene glycol in 
addition to all crystallization condition reagents and soak components at the same 
concentrations as in the growth conditions. Crystals were screened for diffraction on the home 
source Bruker X8 Prospector system. Diffracting crystals were stored in liquid nitrogen for up to 
6 months. Diffraction data was collected at Beamline 19-ID of the Advanced Photon Source 
(Argonne National Laboratory, Chicago, IL). Data was integrated and scaled with the HKL3000 
software suite (108). Rigid body, restrained refinement and TLS (translational/libration/screw) 
refinement were performed using RefMac5 in the CCP4 V6.5.019 Suite (109, 110). Parameters 
for TLS refinement were obtained using the TLS Motion Determination online server (111). 
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Modeling and visualization was performed using WinCoot V0.82 and PyMol V0.99 (DeLano 
Scientific LLC, San Francisco, CA) (112).  
 
5. Mammalian Cell Culture Assays 
The MDA-MB-468 triple-negative breast cancer cell line was obtained from the lab of Dr. 
Clark D. Wells (Indiana University Medical School, Indianapolis, IN), and was used for all cell 
culture assays (113). Dulbecco’s Modification of Eagle’s Medium (DMEM, 1 X) with 4.5 g/L 
glucose and L-glutamine without sodium pyruvate, supplemented with 10 % fetal bovine serum 
(FBS), 100 units/mL of penicillin, and 10 µg/mL of streptomycin, was used as the growth 
medium.  Cells were subcultured at 60-80 % confluency by washing with phosphate-buffered 
saline (PBS) (GE Healthcare, Little Chalfont, UK), incubating with Trypsin 0.25 % 0.2 g/L EDTA 
((GE Healthcare, Little Chalfont, UK) until cells detached, and transferring to fresh medium in a 
1:5 ratio.  
For experimental assays, cells were plated on the Matrigel Matrix basement membrane. 
Matrigel was thawed on ice overnight before use. 40 µL of 7 mg/mL Matrigel was plated per 
well on 96-well plates, and incubated at 37 °C for 30 minutes before use. 5000 MDA-MB-468 
cells were then plated per well. Compound treatment was performed at 0.5 % DMSO and 
initiated synchronously with plating on Matrigel. Media and compound were changed every 48 
hours. An MTT assay was used to measure cell proliferation and viability. The protocol for the 
use of the MTT assay in conjunction with Matrigel Matrix was based on previously published 
work (114). The wells were first washed with PBS. 100 µL of 0.5 mg/mL MTT reagent (Thermo 
Fisher Scientific, Waltham, MA) in PBS was added per well. Plates were incubated at 37 °C to 
allow reduction of the dye. 100 µL of 10 % Sodium-Dodecyl Sulfate (SDS), 0.05 N HCl was added 
per well. The plates were, again, incubated at 37 °C for 4 hours to promote cell lysis and 
Matrigel solubilisation. Absorbance readings were taken at 595 nm using the Spectramax 340PC 
plate reader (Molecular Devices, Sunnyvale, CA). All measurements were normalized to the 
Matrigel control wells, which contained no cells, compounds, or DMSO. Measurements were 
interpreted as a ratio to the DMSO control.  
𝑀𝑇𝑇 𝑠𝑖𝑔𝑛𝑎𝑙 𝑟𝑎𝑡𝑖𝑜 =
𝐴595 𝑎𝑓𝑡𝑒𝑟 𝑖𝑛𝑐𝑢𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑟𝑒𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
𝐴595 𝑎𝑓𝑡𝑒𝑟 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑡ℎ𝑒 𝑎𝑏𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
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III. Results 
A. CM38 Inhibitor Properties and Structure-Activity Relationship 
The CM38 compound was identified as a hit in the esterase high-throughput screen 
(115). The compound showed good structural characteristics as a lead compound, having a low 
molecular weight of 294 kDa and an approximate logP of 2.8 (Figure 11A). To further 
characterize the compound, it was screened for aldehyde dehydrogenase inhibition with 9 
aldehyde dehydrogenase isoenzymes at 20 µM (Figure 11B). CM38 showed excellent selectivity 
for ALDH1A1 over the other, highly similar isoenzymes in the subfamily. CM38 also 
demonstrated respectable potency as an ALDH1A1 inhibitor with an IC50 value of 440 ± 37 nM 
and a Ki of 320 ± 14 nM. CM38 was found to be uncompetitive with respect to varied NAD+, 
which is consistent with the idea that it does not bind the cofactor-binding site (Figure 12). 
Based on these characteristics, CM38 was chosen as a lead compound in structure-activity 
relationship development.  
 
Figure 11: Characterization of CM38 as an Aldehyde Dehydrogenase Inhibitor.  
A) Structure of the CM38 compound. B) Selectivity screen of CM38 with 8 human aldehyde 
dehydrogenase enzymes and 1 rat aldehyde dehydrogenase enzyme. C) Dose-response curve of 
CM38 with the ALDH1A1 isoenzyme.  
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Figure 12: Lineweaver-Burk Plot of CM38 Inhibition of ALDH1A1 with Varied NAD+  
CM38 inhibition is uncompetitive with respect to varied NAD+, and has a Ki of 320 ± 14 nM 
 
Compounds with high structural similarity to CM38 were ordered from commercial 
sources and evaluated as ALDH1A1 inhibitors. Compounds that showed minimal ALDH1A1 
inhibition are summarized in Table 3. These compounds allowed the initial development of the 
CM38 structure-activity relationship by highlighting structural elements that are critical for 
aldehyde dehydrogenase inhibition. In particular, analogues missing the piperidine ring 
(57919133, 5798949 and C629-0256) showed minimal to no inhibition of ALDH1A1. Similarly, 
compounds where the fourth ring was separated from the main three-ring body by a linker 
(C629-0004, C629-0198 and C629-0250) also had a severely reduced ability to inhibit ALDH1A1.  
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Table 3: CM38 Analogues that are Relatively Inactive as ALDH Inhibitors 
Compound ID Compound Structure 
ALDH1A1 Rate Ratio to 
Control at 20 µM of 
Compound 
(± STDEV) 
57919133 
 
0.66 ± 0.013 
5798949 
 
0.58 ± 0.025 
C629-0004 
 
0.49 ± 0.037 
C629-0198 
 
0.58 ± 0.016 
C629-0256 
 
1.14 ± 0.010 
C629-0250 
 
0.97 ± 0.025 
F210-0074 
 
0.59 ± 0.13 
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CM38 compounds that demonstrated the ability to inhibit ALDH1A1 are summarized in 
Table 4. These compounds helped develop the structure-activity relationship of CM38 even 
further by identifying structural changes of the CM38 compound that are tolerated in the 
context of ALDH inhibition. Notably, all compounds have good selectivity for ALDH1A1 and do 
not significantly inhibit the other isoenzymes. These compounds show that the furan ring of the 
CM38 structure may be rotated in orientation (7998070) or converted to a pyrrole (C186-0036, 
C618-0097) with only a modest loss in potency. Similarly, the pyridine ring may be converted to 
a benzene (7998070) or a pyran ring (C186-0036). The methyl group on the pyrrole ring is not 
essential, and may be removed (7998070) or replaced with a carbonyl (C186-0036) or chloride 
(C618-0097) substitution. However, it should be noted that the removal of this methyl does 
appear to drastically lower the selectivity of the compound against ALDH2 (7998070). 
Compound 7998070 is of particular note in this compound series, as many more commercial 
compounds are available for it than for the original CM38 parent compound. Due to the close 
structural similarity and similar ALDH inhibition properties, it may be assumed that 7998070 
binds and inhibits ALDH1A1 through an identical mechanism to CM38 (Figure 13). As such, any 
structure-activity relationship results obtained from 7998070 analogues can also be applied to 
the CM38 compound.  Thus, 7998070 was chosen as a new parent compound to further develop 
the structure-activity relationship of this compound series.  
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Table 4: CM38 Analogues that are Active as ALDH Inhibitors 
 
Compound ID Structure 
ALDH1A1 
IC50 
ALDH1A2 
Rate ratio to 
Control at 20 
µM  
ALDH1A3 
Rate ratio to 
Control at 20 
µM 
ALDHALDH2 
Rate ratio to 
Control at 20 
µM 
ALDH1B1 
Rate ratio to 
Control at 20 
µM 
CM38 
 
440 ± 37 nM 0.82 ± 0.024 0.69 ± 0.025 0.94 ± 0.094 0.86 ± 0.023 
7998070 
 
1.3 ± 0.079 µM 0.81 ± 0.0062 1.02 ± 0.086 0.49 ± 0.024 0.88 ± 0.076 
C186-0036 
 
500 ± 20 nM 0.65 ± 0.026 1.14 ± 0.047 0.86 ± 0.027 0.77 ± 0.028 
C618-0097 
 
1.3 ± 0.13 µM 0.53 ± 0.15 1.04 ± 0.080 0.81 ± 0.015 0.76 ± 0.086 
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Figure 13: Characterization of 7998070 as an Aldehyde Dehydrogenase Inhibitor.  
A) Structure of the 7998070 compound. B) Selectivity screen of 7998070 with 8 human aldehyde 
dehydrogenase enzymes and 1 rat aldehyde dehydrogenase enzyme. C) Dose-response curve of 
7998070 with the ALDH1A1 isoenzyme.  
 
Commercially available analogues of compound 7998070 that did not significantly 
inhibit ALDH1A1 are summarized in Table 5. As was the case with CM38, the 7998070 structure-
activity relationship demonstrates that the piperidine ring is critical, and its removal has a 
dramatic adverse effect on ALDH inhibition (9004424). Additionally, the substitution of the 
piperidine ring with a morpholine ring (9018056) or a piperazine with a cyclohexane sidechain 
(C629-0173) is not tolerated. This likely confirms that the piperidine ring has to remain relatively 
non-polar in order to inhibit ALDH1A1. Additionally, removing one of the rings in the three-ring 
structure also minimizes inhibition, suggesting that the three-ring body of the compound is also 
critical.  
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Table 5: 7998070 Analogues that are Relatively Inactive as ALDH Inhibitors 
Compound ID Compound Structure 
ALDH1A1 Rate Ratio to 
Control at 20 µM of 
Compound  
9004424 
 
0.73 ± 0.052 
9018056 
 
0.80 ± 0.018 
35004881 
 
0.76 ± 0.029 
9087477 
 
0.44 ± 0.027 
C629-0173 
 
0.77 ± 0.059 
 
Analogues of 7998070 that inhibited ALDH1A1 and were further characterized are 
summarized in Table 6. Most notably, this group of compounds demonstrates that as long as the 
piperidine ring is in position, it can tolerate expansion to an azepane (9040591) or addition of 
 36 
methyl side chains at the meta and para positions (9129602, 9129634) with no loss of potency 
toward ALDH1A1. However, reducing the size of the piperidine ring to a pyrrolidine (9031547) 
strongly reduces ALDH inhibition. Compounds E003-0974 and C893-0789 are of particular 
interest in this series. The conversion of one of the aromatic rings in the three-ring body of the 
compound to a single-unsaturated oxane with a carbonyl side-chain (E003-0974, C893-0789) 
actually improves the potency of the compound toward ALDH1A1, with the IC50 lowering from 
1.3 µM for the 7998070 parent compound to 300 nM for C893-0789. Although E003-0974 and 
C893-0789 both feature hydrophobic side-chains on the third ring, the reduction of this 
sidechain from a cyclohexane to an ethyl and methyl (between E003-0974 and C893-0789) had 
no adverse effects on potency. Therefore, this indicates that the oxane and carbonyl groups are 
likely responsible for the improved potency seen in these compounds.  
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Table 6: 7998070 Analogues that are Active as ALDH Inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Structure 
ALDH1A1 
IC50 
ALDH1A2 
Rate ratio to 
Control at 20 
µM  
 
ALDH1A3 
Rate ratio to 
Control at 20 
µM 
 
ALDH2 
Rate ratio to 
Control at 20 
µM 
 
ALDH1B1 
Rate ratio to 
Control at 20 
µM 
 
9040591 
 
1.5 ± 0.12 
µM 
0.85 ± 0.013  1.03 ± 0.098 0.62 ± 0.0098 0.94 ± 0.0050 
9031547 
 
6.7 ± 1.3 µM  0.97 ± 0.031 0.87 ± 0.032 0.53 ± 0.028 1.09 ± 0.044 
E003-0974 
 
560 nM ± 
110 nM 
0.63 ± 0.042 0.85 ± 0.040 0.76 ± 0.30 0.67 ± 0.039 
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Table 6: Continued 
 
 
Compound Structure 
1A1 
IC50 
1A2 
Rate ratio to 
Control at 20 
µM 
 
1A3 
Rate ratio to 
Control at 20 
µM 
 
ALDH2 
Rate ratio to 
Control at 20 
µM 
 
1B1 
Rate ratio to 
Control at 20 
µM 
 
C893-0789 
 
300 ± 14 nM 0.58 ± 0.031 1.11 ± 0.032 0.85 ± 0.0093 0.60 ± 0.019 
9129602 
 
1.4± 0.18µM 0.62 ± 0.050 0.61 ± 0.0065 0.71 ± 0.026 0.73 ± 0.032 
9129634 
 
1.3± 0.10µM 0.72 ± 0.0086 1.03 ± 0.21 0.68 ± 0.028 0.79 ± 0.090 
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B. CM10 Inhibitor Properties and Structure-Activity Relationship 
CM10 was identified along with CM38 in the esterase high-throughput screen for 
ALDH1A1 modulators. It had good basic qualities as a lead compound, featuring a size of 321 
kDa and an estimated logP of 4.82. One liability of the compound was the potentially reactive 
alkene group (Figure 14A). The compound was screened as an ALDH inhibitor with other a range 
of ALDH isoenzymes (Figure 14B). Unlike CM38, CM10 was not selective for ALDH1A1 and also 
inhibited ALDH1A2, ALDH1A3, and ALDH1B1. However, the compound did not inhibit ALDH2, 
which likely means that it is selective only for the ALHD1A subfamily and ALDH1B1.  Dose-
response curves (Figure 14C) showed that the compound had the highest potency with 
ALDH1A2 and ALDH1A3. Moreover, it was a partial inhibitor of ALDH1A1, and reached only a 
minimum rate ratio to control of 0.30 on the IC50 curve. Steady-state kinetics showed that 
ALDH1A1 inhibition was mixed partial with respect to varied NAD+, and had a Ki of = 1.6 ± 0.34 
µM (Figure 15). Due to a very interesting selectivity profile and the potential to develop into a 
therapeutically applicable ALDH1A-selective inhibitor, the CM10 compound was chosen for 
further characterization through the assembly of a structure-activity relationship.  
 
Figure 14: Characterization of CM10 as an Aldehyde Dehydrogenase Inhibitor 
A) Structure of the CM10 compound. B) Selectivity screen of CM10 with 8 human aldehyde 
dehydrogenase enzymes and 1 rat aldehyde dehydrogenase enzyme. C) Dose-response curves of 
CM10 with the ALDH1A1, ALDH1A2, ALDH1A3, and ALDH1B1 isoenzymes.  
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Figure 15: Lineweaver-Burk Plot of CM10 Inhibition of ALDH1A1 with Varied NAD+  
CM10 inhibition is mixed partial with respect to varied NAD+, and has a Ki of 1.6 ± 0.34 µM 
 
Commercially available analogues of CM10 were evaluated as inhibitors of the ALDH1 
family. The compounds that were not found to inhibit any ALDH1 isoenzymes are summarized in 
Table 7. Most of these compounds lack the hydroxyl of the phenol group (Y020-7301, D010-
0120, D010-0112, 6738-0091) leading to the interpretation that this hydroxyl group is essential 
for ALDH inhibition. The only inactive CM10 analogue to feature the phenol ring is compound 
6738-0174. In this case, the reasonable interpretation is that the compound scaffold does not 
tolerate a bulky adduct, such as a morpholine ring, on the alkyl side-chain.  
CM10 analogues that inhibited ALDH1A enzymes were, for the most part, partial 
inhibitors. Since this is a property shared by the parent compound CM10, it is likely inherent to 
the scaffold and its binding mode. One of the early priorities in the development of the CM10 
structure-activity relationship was the determination of the role of the potentially-reactive 
alkene group. The structure-activity relationship shows that while the alkene group does play a 
role in determining the inhibition characteristics of the compound, it is not absolutely crucial for 
inhibition. Removal of the alkene chain modestly reduced the potency of the compound with 
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ALDH1A1, ALDH1A2, and ALDH1B1 (3988-0434). Replacement of the side chain with an ether 
group at the same position strongly reduced ALDH1A2 and ALDH1B1 inhibition, but improved 
ALDH1A1 inhibition, thereby producing a compound selective for ALDH1A1 and ALDH1A3 (3988-
0587). Removal of the alkene and addition of chloride groups at the 2- and 4- positions on the 
phenol produced a compound that is a highly potent ALDH1A1 and ALDH1A3 inhibitor; however, 
the compound loses selectivity and shows minor inhibition of ALDH2 (3988-0474). Removal of 
the alkene group and the addition of a benzyl ring onto the phenol improves ALDH1A1 inhibition 
but reduces inhibition of the other ALDH1A isoenzymes. This produces a more selective 
ALDH1A1 inhibitor (3988-0485). Overall, the structure-activity relationship suggests that the 
alkene group is suboptimal for ALDH1A1 or ALDH1A3 inhibition; however, the group does 
appear to be key for high potency toward ALDH1A2.   
The most interesting aspect of the CM10 structure-activity relationship is the variety of 
ways in which the inhibitor selectivity can be modified. Branching of the linker between the 
phenol and the two-ring structure eliminated inhibition of ALDH1A1 and produced ALDH1A3-
selective compounds (3988-0506, 3988-0580). On the other hand, branching or extending the 
alkyl side chain on the two ring structure eliminated ALDH1A3 inhibition, producing compounds 
with excellent selectivity for ALDH1A1 (5519-0624, 3988-0486).   
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Table 7: CM10 Analogues that are Relatively Inactive as ALDH Inhibitors 
 
 
 
Compound Structure 
ALDH1A1 
Rate Ratio to 
Control at 20 
µM 
ALDH1A2 
Rate Ratio to 
Control at 20 
µM 
ALDH1A3 
Rate Ratio to 
Control at 20 
µM 
ALDH2 
Rate Ratio to 
Control at 20 
µM 
ALDH1B1 
Rate Ratio to 
Control at 20 
µM 
Y020-7301 
 
1.0 ± 0.016 1.03 ± 0.0031 1.07 ± 0.12 0.92 ± 0.014 1.06 ± 0.015 
D010-0120 
 
1.0 ± 0.0067 1.02 ± 0.031 1.22 ± 0.047 0.87 ± 0.020 1.07 ± 0.015 
D010-0112 
 
1.01 ± 0.023 1.03 ± 0.027  1.10 ± 0.049 0.91 ± 0.0070 1.02 ± 0.041 
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Table 7: Continued 
Compound Structure 
ALDH1A1 
Rate Ratio to 
Control at 20 
µM 
ALDH1A2 
Rate Ratio to 
Control at 20 
µM 
ALDH1A3 
Rate Ratio to 
Control at 20 
µM 
ALDH2 
Rate Ratio to 
Control at 20 
µM 
ALDH1B1 
Rate Ratio to 
Control at 20 
µM 
6738-0091 
 
0.99 ± 0.033 0.97 ± 0.012 1.07 ± 0.031 0.86 ± 0.014 0.98 ± 0.031 
6738-0174 
 
0.86 ± 0.034 0.66 ± 0.064 0.63 ± 0.021 0.91 ± 0.064 0.70 ± 0.039 
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Table 8: CM10 Analogues that are Active as ALDH Inhibitors 
IC50 < 1 µM IC50 > 1 µM, Act. at 20 µM 
<0.5 
0.4 <Act. at 20 µM <0.8 Act. at 20 µM >0.8 
 
Compound Structure 
ALDH1A1 
(Min. Activity) 
ALDH1A2 
(Min. 
Activity) 
ALDH1A3 
(Min. 
Activity) 
ALDH2 
(Min. 
Activity) 
ALDH1B1 
(Min. 
Activity) 
CM010 
 
IC50= 1600 ± 100 nM 
(0.30) 
 
IC50= 540 ± 
54 nM 
(0.05) 
IC50= 630 ± 
64 nM 
(0.11) 
Act. at 20 
µM= 0.88 ± 
0.037 
IC50= 1200 ± 
120 nM 
(0.073) 
5519-0628 
 
IC50= 2.8 ± 0.35 µM 
(0.35) 
IC50= 820 ± 
43 nM 
(0.09) 
IC50= 1.2 ± 
0.13 µM 
(0.24) 
Act. at 20 
µM= 0.84 ± 
0.018 
IC50= 1.2 ± 
0.081 µM 
(0.20) 
3988-0434 
 
IC50= 3.7 ± 0.38 µM 
(0.26) 
IC50= 2.7 ± 
0.32 µM 
(0.33) 
IC50= 700 ± 
45 nM 
(0.27) 
Act. at 20 
µM= 0.87 
±0.027 
IC50= 2.1 ± 
0.23 µM 
(0.4) 
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Table 8: Continued 
Compound Structure 
ALDH1A1 
(Min. Activity) 
ALDH1A2 
(Min. 
Activity) 
ALDH1A3 
(Min. 
Activity) 
ALDH2 
(Min. 
Activity) 
ALDH1B1 
(Min. 
Activity) 
3988-0451 
 
IC50= 3.3 ± 0.44 µM 
(0.30) 
Act. at 20 
µM= 0.61  ± 
0.062 
IC50= 4.3 ± 
1.6 µM 
 
Act. at 20 
µM= 0.77 ± 
0.0056 
Act. at 20 
µM= 0.60 ± 
0.026 
3988-0474 
 
IC50= 300 ± 41 nM 
(0.16) 
 
IC50= 3.2 ± 
1.2 µM 
 
IC50= 520 ± 
39 nM 
 
Act. at 20 
µM= 0.49 ± 
0.044 
IC50= 1.9 ± 
0.23 µM 
 
3988-0506 
 
Act. at 20 µM= 1.03  
± 0.011 
IC50= 7.1 ± 
2.5 µM 
(0.37) 
 
IC50= 3.1 ± 
0.73 µM 
(0.23) 
 
Act. at 20 
µM= 0.86 ± 
0.013 
Act. at 20 
µM= 0.59  ± 
0.0096 
3988-0580 
 
Act. at 20 µM= 0.75 
± 0.023 
IC50= 3.1 ± 
0.29 µM 
(0.42) 
 
IC50= 730 ± 
86 nM 
(0.21) 
 
Act. at 20 
µM= 0.94 ± 
0.032 
Act. at 20 
µM= 0.47 ± 
0.018 
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Table 8: Continued 
Compound Structure 
ALDH1A1 
(Min. Activity) 
ALDH1A2 
(Min. 
Activity) 
ALDH1A3 
(Min. 
Activity) 
ALDH2 
(Min. 
Activity) 
ALDH1B1 
(Min. 
Activity) 
3988-0485 
 
IC50= 780 ± 78 nM 
(0.18) 
IC50= 2.2 ± 
0.28 µM 
(0.49) 
IC50= 1.8 ± 
0.50 µM 
(0.24) 
IC50= 0.65 ± 
0.073 
IC50= 4.4 ± 
0.87 µM 
(0.58) 
5519-0624 
 
IC50= 2.3 ± 0.22 µM 
(0.28) 
Act. at 20 
µM= 0.62 ± 
0.086 
Act. at 20 
µM= 1.01 ± 
0.031 
Act. at 20 
µM= 0.76 ± 
0.049 
Act. at 20 
µM= 0.86 ± 
0.029 
3988-0486 
 
IC50= 620 ± 59 nM 
(0.33) 
Act. at 20 
µM= 0.98 ± 
0.11 
Act. at 20 
µM= 0.97 ± 
0.060 
Act. at 20 
µM= 0.85 ± 
0.087 
Act. at 20 
µM= 1.01 ± 
0.052 
3988-0587 
 
IC50= 750 ± 74 nM 
(0.20) 
IC50= 9.5 ± 
8.9 µM 
(0.18?) 
IC50= 620 ± 
67 nM 
(0.28) 
Act. at 20 
µM= 0.85 ± 
0.020 
IC50= 7.6 ± 
0.97 µM 
(0.4) 
3988-0586 
 
IC50= 3.8 ± 0.60 µM 
(0.45) 
IC50= 8.7 ± 
3.7 µM 
(0.26) 
Act. at 20 
µM= 0.99 ± 
0.025 
Act. at 20 
µM= 0.83 ± 
0.017 
Act. at 20 
µM= 0.51 ± 
0.029 
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C. X-ray Crystallography of ALDH1A1 in Complex with CM38 and CM10 
  In order to characterize the binding mode of the CM38 and CM10 compound 
series and better explain their varied selectivity profiles, an X-ray crystallography approach was 
used. X-ray diffraction datasets were collected for ALDH1A1 in complex with CM38 and the 
CM10 analogue 3988-0485. The complex with CM38 was formed by soaking the crystal with the 
CM38 compound and the NAD+ cofactor. The complex with 3988-0485 was formed by co-
crystallization. The space groups and cell dimensions match the apo-enzyme ALDH1A1 structure 
previously published, indicating the presence of the same ALDH1A1 crystal isoform (Table 9) 
(104). The CM38 and CM10 structures were collected at resolutions of 1.8 Å and 1.65 Å, 
respectively. The CM38 structure was refined successfully to a Rwork/Rfree of 0.18 / 0.23. The 
3988-0485 structure, on the other hand, showed only partial compound occupancy. As such, the 
ALDH1A1-39880485 crystal structure should be interpreted with less confidence; however, it 
still holds value for forming hypotheses and making potential interpretations of the structure-
activity relationship. 
 
Table 9: Data Collection and Refinement Statistics for the structures of ALDH1A1 in Complex 
with CM38 and 3988-0485  
 ALDH1A1-CM38 ALDH1A1-39880485 
Data Collection 
Space Group P422 P422 
Cell Dimensions   
   a, b, c (Å) 109, 109, 83 109, 109, 83 
   Α, β, γ (°) 90, 90, 90 90, 90, 90 
Resolution (Å) 50-1.8 50-1.65 
R merge 0.09 (0.50) 0.07 (0.70) 
I/σ  24.4 (3.2) 34 (3.6) 
Completeness (%) 95.6 (77.6) 100 (99.9) 
Redundancy  12.9 (9.9) 12.6 (11.3) 
Refinement Statistics 
Number of Reflections 42449 57482 
Rwork/Rfree 0.18 / 0.23 0.24 / 0.28 
Number of atoms 4320 4085 
   Protein 3853 3852 
   Ligand/Ion 69 28 
   Water 398 205 
RMS Deviations   
   Bond Lengths (Å) 0.011 0.019 
   Bond Angles (°) 1.6 1.8 
 
 48 
 The structure of CM38 bound to ALDH1A1 shows that CM38 binds within the 
substrate binding pocket of the enzyme (Figure 16). The compound binds very close to the 
catalytic residue (Cys303) and appears to interact with the adjacent residue (Cys302). Cys302 
forms contacts with the nitrogen of the piperidine ring and the oxygen of the furan ring. The 
three-ring body of the compound binds in parallel to Tyr297, and forms pi-stacking interactions 
with its aromatic ring. Val 460 is a key residue that helps shape the hydrophobic pocket that 
accommodates the piperidine ring.  
 
Figure 16: Structure of ALDH1A1 in Complex with CM38 
A) Electron density maps of CM38 with the final refined 2Fo – Fc (σ = 1.0) map is shown in blue 
and the original Fo – Fc (σ = 2.5) map is shown in green. B) The binding location of CM38 within 
the substrate binding pocket. Cys302 is highlighted in yellow.  
 
3988-0485 also appears to bind within the substrate-binding pocket in its crystal structure 
(Figure 17). In contrast to CM38, the compound does not bind immediately adjacent to the 
catalytic residue, and is located a little further out of the catalytic pocket. The hydroxide of the 
phenol ring appears to form a hydrogen bond with Trp178. Phe171 forms pi-stacking 
interactions with the imidazole-benzene ring system.  
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Figure 17: Structure of ALDH1A1 in Complex with CM10 Analogue 3988-0485  
A) Electron density maps of 3988-0485 with the final refined 2Fo – Fc (σ = 1.0) map is shown in 
blue and the original Fo – Fc (σ = 2.5) map is shown in green. B) Binding location of 3988-0485 
within the substrate binding pocket. The catalytic residue Cys303 is highlighted in red.  
 
D. Characterization of the CM38 and CM10 Compound Series in Cell Culture 
 In order to evaluate the effectiveness of the CM38 and CM10 compound 
series in cell culture, both a cell line and a quantitation method had to be chosen. The MDA-MB-
468 human triple-negative breast cancer cell line was previously shown to contain a 
subpopulation of cells with high ALDH activity (116) Additionally, it has been found that this cell 
line is sensitive to ALDH1A1 modulators when grown on the Matrigel basement membrane 
(unpublished, Matthew Martien, Dr. Wells Lab, Indiana University Medical School). For these 
reasons, the MDA-MB-468 cell line was chosen for cell culture assays, with all inhibitor 
treatment performed on cells grown on the Matrigel basement membrane. A valid approach for 
measuring cell viability and proliferation after compound treatment also had to be established. 
The MTT assay is a convenient and often used cell assay to measure cell viability. A validation 
assay was performed to ensure that the MTT assay could be reliably used to evaluate the 
viability of MDA-MB-468 cells when grown on Matrigel. Cells were plated at initial densities of 
1000, 4000 and 16000 cells/ well, and the MTT assay was performed after 1, 3, and 5 days. The 
results showed a clear distinction between all three initial densities (Figure 18). The results were 
also consistent with the expected growth pattern of cultured cells, having a lag phase and an 
exponential growth phase. According to these results, the MTT assay is a valid method of 
measuring cell viability and proliferation of the MDA-MB-468 cell line grown on Matrigel. As 
such, this methodology was used for all cell culture assays.  
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Figure 18: MTT Assay Validation 
MDA-MB-468 cells were plated at three different densities on the Matrigel Basement 
Membrane. The MTT assay was used to measure cell viability at three time points.  
  
 Several compounds from the CM38 compound series were screened for 
activity in cell culture. The tested compounds were chosen based on their physical properties 
and their activity as ALDH inhibitors. Two compounds (C629-0250 and 9018056), which were not 
effective as ALDH inhibitors in vitro, were also used in the assay as negative controls. Cells were 
treated with 30 µM of compound for 5 days, after which the MTT assay was performed. A 
number of compounds were found to successfully reduce the viability and/or proliferation of 
the cells in the assay (Figure 19). The parent compound had an MTT signal ratio to DMSO control 
of 0.24 ± 0.044; the E003-0974 compound was even more effective, with an MTT ratio to control 
of 0.048 ± 0.015. Both of these compounds were among the most potent ALDH1A1 inhibitors in 
vitro, which is a positive sign that suggests the observed effect is due, at least in part, to 
ALDH1A1 inhibition. However, the screen also revealed a potential concern about the CM38 
compound series. The negative controls (C629-0250 and 9018056) both showed an MTT ratio to 
control of below 0.8, with the C629-0250 negative control showing high potency with a ratio of 
0.16 ± 0.0043. This may suggest that the CM38 scaffold has some general toxicity, and that at 
least some of the observed effect in the MTT screen is independent of ALDH inhibition.  
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Figure 19: MTT Screen of CM38 Analogues at 30 µM 
Screen conducted on MDA-MB-468 cells plated on Matrigel. MTT assay performed after 5-day 
incubation.  
 
 CM10 series compounds were screened in the same way as CM38 
compounds, including two negative control compounds (Figure 20). Unlike in the CM38 series, 
the CM10 negative control compounds (D010-0112 and 6738-0174) showed minimal 
effectiveness in the assay, giving no reason to suspect off-target toxicity from this scaffold. 
Overall, compounds that were selective for isoenzymes other than ALDH1A1 (such as 3988-0434 
and 3988-0580) performed poorly in the assay, suggesting that ALDH1A1 plays the dominant 
role in the MDA-MB-468 cell line. On the other hand, compounds that showed potent inhibition 
of ALDH1A1 in vitro (such as 3988-0485, 3988-0486, and 3988-0474) all showed good potency in 
the MTT screen. Compounds CM10, 3988-0485 and 3988-0486 were chosen for further 
characterization in cell culture based on their excellent effectiveness in the screen.  
 52 
 
Figure 20: MTT Screen of CM10 Analogues at 30 µM 
Screen conducted on MDA-MB-468 cells plated on Matrigel. MTT assay performed after 5-day 
incubation.  
 
 CM10 and two of its analogues, 3988-0485 and 3988-0486, were tested for a 
dose dependent response in the MTT assay (Figure 21). The three inhibitors demonstrated a 
clear dose-dependent response and relatively high effectiveness. All three compounds showed a 
similar degree of potency, having LC50 values of 18 ± 4.3 µM for CM10, 13 ± 6.1 µM for 3988-
0485, and 15 ± 2.3 µM for 3988-0486. CM10, however, demonstrated a visibly lower Hill slope 
than its two analogues.  
 
 
Figure 21: Dose-Response Curves of CM10 Series Compounds 
Assay conducted on MDA-MB-468 cells plated on matrigel. MTT assay performed after 5-day 
incubation. A) Dose-response curve of CM10 B) Dose-response curve of CM10 analogue 3988-
0485 C) Dose-response curve of CM10 analogue 3988-0486 
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IV. Discussion 
A. Structural Features of the ALDH1 Active Site in Inhibitor Design 
Despite the many known roles of aldehyde dehydrogenases, the specific roles of ALDH1 
isoenzymes in healthy or pathogenic pathways remain unclear. Isoenzyme-selective inhibitors 
could be a key tool to help delineate the roles of each isoenzyme in biological processes. In spite 
of their potential importance, currently, no commercially available inhibitors show selectivity for 
the ALDH1A subfamily or individual ALDH1A isoenzymes (39). Available structural data suggests 
that the active site of ALDH1A features key differences when compared to ALDH2 and ALDH3 
isoenzymes, indicating that it may be possible to develop inhibitors with the desired selectivity. 
As such, development of isoenzyme-selective ALDH1A inhibitors is a promising and yet-
unexplored niche in aldehyde dehydrogenase research.  
Currently available x-ray crystallography structures include those of ALDH1A1, ALDH2, 
and ALDH3A1. Comparing the active sites of the three structures, some major differences in the 
architecture of the active site become obvious (Figure 22). The ALDH1A1 structure features an 
open, conical substrate-binding pocket. The ALDH2 active site is more cylindrical, while the 
ALDH3A1 site is even more narrow and twisting. ALDH1A1 has the most accessible active site, 
meaning that modulators and substrates with large, planar structures are likely to be selective 
for the ALDH1 family. CM38 and CM10 compound series, which both feature planar multi-ring 
systems in the scaffold, are likely selective for ALDH1 enzymes because of this topological 
difference in shape of the substrate-binding pocket. Notably, while CM10 series compounds are 
selective against ALDH2, some still inhibit ALDH1B1. This suggests that while ALDH1B1 is, 
phylogenetically, more closely related to ALDH2, its substrate-binding site may actually 
resemble that of the ALDH1A subfamily. Thus, the CM10 SAR provides some insight into the 
structure of ALDH1B1, for which a crystal structure is not yet available. 
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Figure 22: Architecture of the ALDH1A1, ALDH2, and ALDH3A1 Substrate-Binding Sites 
Structures obtained from PDB. PDB IDs: 4WJ9, 1O04, 3SZA (104, 117, 118). 
A) Active site of ALDH1A1, with the catalytic cysteine highlighted in red. B) Active site of ALDH2, 
with the catalytic cysteine highlighted in red. C) Active site of ALDH3A1, with the catalytic 
cysteine highlighted in red. D) Cross-section of the ALDH1A1 active site, demonstrating the 
cone-shaped, accessible substrate-binding pocket E) Cross-section of the ALDH2 active site, 
showing the cylindrical structure F) Cross-section of the ALDH3A1 active site, showing the 
narrow, winding architecture.  
The binding mode of compounds discussed here can be viewed as an effort to map out 
useful structural features of the active site and facilitate the structure-based drug design of 
future compounds. The crystal structures obtained for CM38 and CM10 compounds can be used 
to identify key residues in the active site that can improve potency and selectivity of 
modulators. CM38 makes contact with Cys302 and π-stacking interactions with Tyr297 (Figure 
23). Both of these interactions are well conserved in the ALDH1 and ALDH2 families, as Cys302 is 
perfectly retained and Tyr297 is only substituted by other aromatic residues (Table 10). In 
ALDH3A1, neither of these contacts are conserved, suggesting that the altered shape of the 
active site is not the only reason for the lack of inhibition. Furthermore, the piperidine ring of 
CM38 occupies a hydrophobic pocket shaped by Phe171, Trp178, Val460, and Phe466. This 
hydrophobic pocket is conserved in ALDH1 and ALDH2 families, but not in ALDH3A1 (Table 10). 
However, Val460 is substituted to the larger Leu in ALDH1A2 and ALDH1A3 and the bulkier Phe 
in ALDH2; this may reduce the space available for the piperidine ring and contribute to the 
ALDH1A1 selectivity of this compound. Despite their relevance, none of the residues mentioned 
so far are able to fully explain the excellent ALDH1A1 selectivity of the CM38 compound series. 
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In fact, the predominant residue responsible for the selectivity is likely Gly458. Gly458 has 
previously been found to play a key role in facilitating the binding of ALDH1A1-selective 
inhibitors (107). The absence of a side chain increases the room available in the ALDH1A1 active 
site and allows the binding of large, planar compounds. Gly458 is not conserved in other ALDH1 
and ALDH2 isoenzymes, meaning that occupying the space afforded by it allows high ALDH1A1 
selectivity. This is the case with CM38, as the three-ring core of the compound would be 
sterically hindered by the presence of a side chain at the 458 position.   
 
Figure 23: Key Residues in the Binding of CM38 to ALDH1A1 
Table 10: Conservation of Key Residues in the ALDH1A1 Active Site in CM38 Binding 
Identical residues are labeled green, similar labeled yellow, and non-conserved labeled red 
ALDH1A1 Phe171 Trp178 Tyr297 Cys302 Gly458 Val460 Phe466 
ALDH1A2 Phe Trp Phe Cys Asn Leu Phe 
ALDH1A3 Phe Trp Phe Cys Asn Leu Phe 
ALDH1B1 Phe Trp Phe Cys Asn Val Phe 
ALDH2 Phe Trp Phe Cys Asp Phe Phe 
ALDH3A1 Tyr Gln Met Thr His Thr Phe 
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The crystal structure of the CM38 binding mode can be further integrated with its 
kinetic properties and the structure-activity relationship of its analogues in order to gain further 
insight and check for consistency. The binding mode in the crystal structure is in agreement with 
the results previously found in steady-state kinetic experiments, as the CM38 compound was 
found to be uncompetitive with respect to NAD+, and, thus, was unlikely to be found in the 
cofactor-binding site. One of the findings of the CM38 SAR was that the piperidine ring is crucial 
for inhibition; loss of the ring, addition of polar elements or expansion with bulky groups 
compromised inhibition (Figure 24). This is in perfect agreement with the crystal structure, as 
the piperidine ring was found to occupy a well-defined hydrophobic pocket. The results of the 
SAR and the crystal structure suggest that this hydrophobic interaction is one of the primary 
drivers of CM38 binding. The oxygen and nitrogen atoms in the three-ring structure were not 
found to be critical, as removing them or altering their position had only a minor effect on 
potency. The crystal structure, again, is largely in agreement. While the oxygen may make polar 
contacts with Cys302 and provide a minor benefit to potency, the nitrogen makes no observable 
contribution to compound binding. The methyl group on the pyrrole was thought to contribute 
to selectivity against ALDH2. The crystal structure has no clear explanation for this, as any 
binding to ALDH2 would have an altered binding mode, due to the alternate active site 
architecture (Figure 22). It is likely that the absence of this methyl makes the compound narrow 
enough to allow suboptimal binding to the more cylindrical ALDH2 substrate-binding site.  
Another finding of the CM38 SAR suggested that the substitution of the terminal ring in the 
three-ring body of the compound with a single-unsaturated oxane and a carbonyl side-chain 
actually improved potency, as seen in compounds E003-0974 and C893-0789. This observation 
cannot be validated with the structure of the CM38-ALDH1A1 co-crystal. It is highly unlikely that 
E003-0974 and C893-0789 have an identical binding mode to CM38. The methyl on the furan 
and the carbonyl on the oxane would sterically clash with Cys302. Furthermore, there is not 
enough space to accommodate the additional alkyl ring seen in E003-0974. As a result, these 
compounds likely feature a binding mode where the main body of the compound is shifted or 
rotated. An additional crystal structure is needed to find the binding mode of these compounds 
and rationalize their improved potency.  
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Figure 24: Summary of CM38 Structure-Activity Relationship 
The CM10 series appears to bind in a slightly different location as compared to CM38 
(Figure 25). Likely the primary interaction for CM10 binding is a hydrogen bond between the 
phenyl hydroxyl of the compound and the amine of Trp178. Trp178 is perfectly conserved in 
ALDH1 and ALDH2 enzymes, explaining the relatively broad selectivity profiles of CM10 
analogues (Table 11). The structure also has a π-stacking interaction with Phe171, which is, 
again, conserved in the ALDH1 and ALDH2 families. Notably, the 3988-0485 compound in the 
obtained crystal structure does not bind immediately adjacent to Gly458, which is a key site for 
ALDH1A1-selective compounds. This likely explains why 3988-0485, like many other compounds 
in the CM10 series, is able to inhibit ALDH1A2 and ALDH1A3. Instead, the 3988-0485 compound 
occupies a space afforded by the lack of a side chain on Gly125. Unlike Gly458, Gly125 is 
conserved within the ALDH1A subfamily, but not by the other ALDH1 and ALDH2 isoenzymes 
(Table 11). Since the presence of a side chain at the 125 position would sterically hinder the 
binding of 3988-0485, Gly125 likely plays a predominant role in defining the ALDH1A selectivity 
of many CM10 series compounds.  
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Figure 25: Key Residues in the Binding of 3988-0485 to ALDH1A1 
Table 11: Conservation of Key Residues in the ALDH1A1 Active Site in 3988-0485 Binding 
Identical residues are labeled green, similar labeled yellow, and non-conserved labeled red 
ALDH1A1 Asn121 Asp122 Gly125 Phe171 Trp178 Gly458 
ALDH1A2 Val Asp Gly Phe Trp Asn 
ALDH1A3 Ile Asp Gly Phe Trp Asn 
ALDH1B1 Leu Asp Glu Phe Trp Asn 
ALDH2 Val Asp Met Phe Trp Asp 
ALDH3A1 Glu Glu Tyr Tyr Gln His 
 
As was the case with CM38, the CM10 SAR is largely in agreement with the proposed 
binding mode of the series. The mixed partial inhibition with respect to NAD+ shown in steady 
state kinetics experiments is consistent with this structure, as the compound is not competing 
with NAD+ for binding. In contrast to CM38, the CM10 series features a more diverse selectivity 
profile, and makes use of more sites in the ALDH1A1 catalytic pocket that can be exploited to 
alter compound specificity. The main group necessary for binding was found to be the hydroxyl 
on the phenol group (Figure 26). This is explained by the crystal structure, in which this hydroxyl 
forms a hydrogen bond with the amine of Trp178. This interaction is likely to be the primary 
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determinant of compound potency of the CM10 series. Based on the SAR, it was thought that 
there is room to expand the compound by addition of groups onto the phenol. The compound in 
the structure, 3988-0485, actually features a benzene at this position. The crystal structure 
shows that there is sufficient room to allow these bulky adducts, as they face largely out of the 
substrate-binding site into solvent. The branching of the linker between the aromatic groups 
with aliphatic side chains was shown to almost entirely eliminate ALDH1A1 inhibition, while 
leaving ALDH1A2 and ALDH1A3 binding relatively intact. In the crystal structure, this branched 
group would come in close contact with Asn121, which, being polar, would not accommodate 
an aliphatic group. However, ALDH1A2 and ALDH1A3 feature Val and Ile, respectively, at this 
position (Table 11). These non-polar residues would be able to form hydrophobic interactions 
with an aliphatic group and, therefore, better accommodate the branch. It would be interesting 
to observe if branching with a polar group or a hydrogen-bonding partner would have the 
reverse effect and improve ALDH1A1 selectivity. Another structural feature important for 
selectivity was the alkyl side chain on the two-ring structure. It was found that lengthening or 
branching this group improved ALDH1A1 selectivity. The crystal structure provides a likely 
mechanism for this observation. While the 3988-0485 structure does not occupy the space 
adjacent to Gly458, the alkyl side chain extends in that direction. It is likely that an extended 
chain occupies this space and, therefore, faces steric clashes from side chains in other 
isoenzymes.  
 
Figure 26: Summary of CM10 Structure-Activity Relationship 
 
Overall, the crystal structures and structure-activity relationships for the CM38 and 
CM10 series identify a number of structural features in the ALDH1A1 active site that may be 
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taken advantage of in modulator design. Cys302 and Trp178 are able to make contacts with 
polar groups, while Phe171 and Tyr297 are available for π-stacking interactions. Slightly deeper 
than the catalytic cysteine in the active site, there exists a hydrophobic pocket that can 
accommodate six or seven-membered rings. Asn121, Gly125, and Gly458 are three residues that 
vary within the ALDH1 and ALDH2 families, thereby allowing the design of isoenzyme-selective 
inhibitors.  
B. CM38 and CM10 Analogues as Lead Compounds in Chemical Tool and Drug Development 
Cancer stem cells are a proposed subpopulation in some cancer types, which may 
contribute to chemotherapy and radiotherapy resistance, cancer relapse, and metastasis. ALDH1 
enzymes have been successfully used as markers of cancer stem cells in multiple tumor types, 
but have been largely unexplored as drug targets. Furthermore, the specific functions of ALDH1 
isoenzymes in cancer biology remain unclear, making it difficult to design specific therapies. 
While the CM38 and CM10 compound series are valuable as a means of mapping the ALDH1 
active site, they can also be useful as putative lead compounds in chemical tool and drug 
development. The ability to use these compounds in living systems would allow the 
identification of specific roles of ALDH1 isoenzymes in healthy and disease pathways, as well as 
potentially the development of compounds to selectively target cancer stem cells. To this end, 
the efficacy of these compound series needs to be fully evaluated in cell and animal models. 
An MTT assay was conducted on MDA-MB-468 cells grown on Matrigel in the presence 
of CM38 analogues. The screen showed warning signs of a potential source of general toxicity in 
the CM38 scaffold, as compounds that did not inhibit ALDH1 in vitro still inhibited cell 
proliferation. CM38 compounds feature an α,β-unsaturated carbonyl group, which is a potential 
source of reactivity for the compound series (Figure 27). The CM38 series should be pursued 
with caution for drug development until this issue is further investigated.  
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Figure 27: Potential Mechanism of the Reactivity of the CM38 Scaffold 
Highlighted in red is the α,β-unsaturated carbonyl group, a potential source of reactivity and 
toxicity in the CM38 series 
 
The CM10 series was also tested in an identical MTT screen. Unlike the CM38 series, the 
CM10 series showed no clear warning signs of potential toxicity in the screen. The negative 
control compounds were not effective and had MTT signal ratios to DMSO control of 0.8 and 
above. Furthermore, the effectiveness of the compounds in the MTT assay was generally 
correlated with the potency of ALDH1A1 inhibition and the logP. This is a positive sign, 
suggesting that the ability to inhibit ALDH1A1 is the primary reason for the effect observed in 
the assay. It also likely indicates that ALDH1A1 is the predominant ALDH1A enzyme in the MDA-
MB-468 cell line, as compounds that were selective for ALDH1A2 or ALDH1A3 were largely 
ineffective. CM10, 3988-0485 and 3988-0486 were found to be the most potent in the MTT 
screen, having LC50 values of 18 ± 4.3 µM, 13 ± 6.1 µM, and 15 ± 2.3 µM, respectively. 3988-
0485 and 3988-0486 are very promising compounds for future development as chemical tools. 
The two have good Lipinski properties, having 4 hydrogen bond acceptors, two donors and a 
molecular weight well below 500Da (Table 12). 3988-0485 has a logP of 4.69, while 3988-0486 
narrowly exceeds the Lipinski guidelines at 5.11. The inhibition properties of these compounds 
make them very interesting as a pair. 3988-0485 inhibits ALDH1A1, ALDH1A2 and ALDH1A3, 
while 3988-0486 is an almost perfectly selective ALDH1A1 inhibitor. Despite the differences in 
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selectivity, the two display nearly identical potency toward ALDH1A1, having IC50 values of 780 ± 
78 nM for 3988-0485 and 620 ± 59 nM for 3988-0486. On top of that, the two compounds are 
nearly identical structurally, having only a one-methyl difference between them. Altogether, 
these properties make this pair of compounds extremely useful for comparing the role of 
ALDH1A1 with that of ALDH1A2 and ALHD1A3 in various cell lines. For example, in the MDA-MB-
468 cell line used here, the two have nearly identical LC50 values, suggesting that ALDH1A2 and 
ALDH1A3 do not significantly contribute to the survival and stemness properties of the cell line. 
In a cell line where ALDH1A1 did not play a dominant role, 3988-0485 would be expected to be 
more effective than 3988-0486. Beside the immediate usefulness of these compounds as 
chemical tools, the potency, effectiveness in cells, and Lipinski properties of these compounds 
make them highly promising for future pharmaceutical development. 
Table 12: Lipinski Properties of Select CM10 Analogues 
Compound Structure 
Freely 
Rotatable 
Bonds 
H-bond 
Acceptors 
H-Bond 
Donors 
LogP 
MW 
(Da) 
3988-0485 
 
5 4 2 4.69 331.42 
3988-0486 
 
6 4 2 5.11 345.45 
 
C. Future Directions 
Although much progress has been made to characterize and develop the CM38 and 
CM10 series, further experiments are still needed to complete this work. In particular, future 
directions should include expanding the structure-activity relationships with more compounds, 
crystallization of new analogues, and cell culture experiments to investigate the selectivity of 
compounds in cells.  
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The most straightforward way to continue this project is to expand the structure-activity 
relationships. New analogues can be used to investigate yet-unexplored structural features of 
the compound or to attempt to capitalize on the things already learned in order to produce 
superior compounds. For the CM38 series, the specific values of the nitrogen in the piperidine 
ring or the carbonyl were never explored in the structure-activity relationship. Replacing the 
nitrogen with a carbon or eliminating the carbonyl group would serve to verify the roles of these 
groups in ALDH1 inhibition (Table 13a,b). Furthermore, it may be possible to replace the 
piperidine ring with a benzene ring (Table 13c). Although it would be less flexible and perhaps a 
worse fit for the hydrophobic pocket, it may also form π-stacking interactions with the nearby 
Phe171 and improve affinity. Another prospect is to use the available SAR of CM38 and its 
crystal structure to guide the design of more potent ALDH1A1 inhibitors. The hydrophobic 
interaction with the piperidine ring plays a key role in binding; therefore, it may be possible to 
improve affinity by enhancing the hydrophobicity of the ring (such as with the addition of 
halogens like chloride) (Table 13d). Compounds E003-0974 and C893-0789 show that 
substitution of the terminal ring with a single-unsaturated oxane containing a carbonyl side-
chain improved potency. It may be possible to produce a better inhibitor by applying this change 
to the more potent CM38 scaffold, rather than the 7998070 scaffold (Table 13e). Since it is 
unlikely that both the carbonyl and the oxane are equally responsible for the improved 
inhibition, one approach may be to keep only one of these groups in new analogues (Table 13f). 
As stated earlier, the α,β-unsaturated carbonyl group is a potential liability in the CM38 scaffold. 
Analogues can be used to investigate if this group can be eliminated without sacrificing 
inhibition. Possible approaches include reducing the α,β-unsaturated bond or replacing the 
carbonyl with an alcohol (Table 13g, h). It may also be possible to sterically occlude the potential 
nucleophilic attack with the addition of a group, such as a methyl, onto the furan ring (Table 
13i). 
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Table 13: Potential Compounds to Expand the Structure-Activity Relationship of CM38 
Objective Possible Analogue Structures 
Test new 
structural 
features 
a) b) c)  
Improve 
potency 
d) e) f)  
Eliminate 
α,β-
unsaturated 
carbonyl 
group 
g) h)  i)  
 
A similar approach of ordering new analogues may also be taken with the CM10 series. 
The importance of the benzene ring in the benzimidazole group may be tested by trying an 
analogue with only an imidazole (Table 14a). The length of the linker between the ring 
structures can also be varied (Table 14b). Although the crucial nature of the hydroxyl has been 
verified, its position has so far not been varied. A hydroxyl at the meta position may still be able 
to hydrogen bond with Trp178, and should be checked as a possible improvement (Table 14c). 
The potency of the CM10 series may be improved by combining features from different potent 
analogues. 3988-0474 was the most potent analogue, but also the least selective. By combining 
the chloride groups that gave it improved potency with the benzene and methyl groups that 
have been shown to improve ALDH1A1 selectivity, it may be possible to produce a more potent 
ALDH1A1 inhibitor (Table 14d). Similarly, by combining the ether of compound 3988-0587 and 
the benzene of compound 3988-0485, it may be possible to surpass the potency of either parent 
compound (Table 14e). Lastly, while a methyl branch at the linker has been shown to eliminate 
ALDH1A1 inhibition, other types of branches have not been attempted. A hydroxyl at this 
position may be able to hydrogen bond with Asn121 and improve potency of ALDH1A1 
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inhibition (Table 14f). While compound 3988-0486 has already demonstrated optimal ALDH1A1 
inhibition, the series also shows untapped potential in developing a highly selective ALDH1A3 
inhibitor. A methyl branch at the linker has been shown to increase ALDH1A3 selectivity, but has 
not been tested with a standard 3988-0434 scaffold (Table 14g). It may also be possible to 
combine features from two good ALDH1A3 inhibitors, 3988-0580 and 3988-0587, in order to 
produce an even more selective ALDH1A3 inhibitor (Table 14h). The original CM10 compound 
showed better inhibition of ALDH1A2 and ALDH1A3 than toward ALDH1A1. Although the alkene 
group was eliminated in order to remove a potential metabolic liability, it may be possible to 
recapture the potency toward ALDH1A2 and ALDH1A3 by replacing the alkene with an alkyl 
(Table 14i).  
Table 14: Potential Compounds to Expand the Structure-Activity Relationship of CM10 
Objective Possible Analogue Structures 
Test new 
structural 
features 
a) b) c)  
Improve 
potency 
d) e)      f)       
Improved 
ALDH1A3 
selectivity 
g) h) i)   
 
Aside from new analogues, other aspects of this project should also be addressed in 
further research. New crystal structures would benefit the validation and development of the 
structure-activity relationships. A better-occupancy structure of any CM10 series compound 
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should be pursued. Since compound occupancy in the crystal is the main issue, co-crystals with a 
more hydrophilic compound may help inhibitor penetration of the crystal. A good candidate is 
compound 3988-0587, which is the most hydrophilic of the ALDH1A1 inhibitors in the current 
SAR. For the CM38 series, new crystal structures with compounds E003-0974 and C893-0789 
would confirm whether or not these compounds assume that same binding mode as CM38.  
Another gap in the data on the CM38 and CM10 compound series is the lack of 
information on their selectivity in cells. This is especially an issue for the CM38 series, as the 
initial cell culture screen suggested that the scaffold may cause off-target toxicity. One approach 
is to test analogues without the α,β-unsaturated carbonyl group, see if the apparent toxicity 
persists. A more universal approach would be to attempt to rescue the cell line following 
compound treatment. ALDH1A1 overexpression in the cell line should be able to rescue the cells 
from the effects of the CM38 and CM10 compounds, if these compounds are acting selectively 
on ALDH1A1. However, since the overexpressed ALDH1A1 would be able to bind and sequester 
the compounds even if they have an off-target effect, this approach would not provide a 
definitive answer. An optimal strategy would be to transfect the cell line with an ALDH1A1 
mutant that is resistant to inhibition by the compounds. For the CM38 analogues, mutation of 
Gly458 to any residue with a bulky sidechain would likely eliminate inhibition. A G458N mutant 
was previously used in a similar strategy for the CM26 and CM37 compounds (107). For the 
CM10 series, the ALDH1A1-selective 3988-0486 would be easiest to use in this type of 
experiment, as it shows excellent selectivity for one isoenzyme. Compound 3988-0486 would 
also likely be unable to inhibit a G458 mutant. If the selectivity of other CM10 compounds needs 
to be evaluated, a G125 mutant may be used in a similar fashion; however, transfection with 
multiple enzyme mutants may need to be done if the cell line is reliant on multiple ALDH1 
isoenzymes. Overall, transfection with an inhibitor-resistant enzyme mutant would be expected 
to rescue the cells following compound treatment if the compounds do not have significant off-
target effects, thus settling the issue on in-cell compound selectivity. An entirely alternate 
approach would be the use of a counter cell line. A “normal” human breast cell line would not 
be expected to be reliant on ALDH1A1 activity, meaning that selective ALDH1A1 inhibitors 
should not have a toxic effect.  
Other cell culture assays can also be used to evaluate the effect of these compounds on 
cell properties and signalling pathways. The compounds may be tested in other cell lines, such 
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as ovarian, lung, and colorectal to verify that they can be effective in multiple cancer cell types. 
Spheroid formation is a cell property indicative of cancer stemness; as such, the impact of CM10 
and CM38 series compounds on a spheroid formation assay may be evaluated. An ALDH1A1 
enzymatic inhibitor has previously been shown to decrease spheroid formation in an ovarian 
cancer cell line, validating this type of experimental approach (93). Similarly, cell invasion may 
be evaluated. Commercially available matrigel invasion assays (Corning Inc., Corning, NY) may be 
used to evaluate the effect of compounds on the invasiveness of cell lines. These types of 
experiments would show the effect of these compounds, and ALDH1A inhibition in general, in a 
greater context. While the compounds presented have been shown to be effective at reducing 
proliferation in a cell line, further experiments are needed to show their effect on other 
stemness properties. By conducting experiments to verify their effect on more clinically relevant 
properties, such as spheroid formation and invasiveness, a much stronger case for the use of 
these compounds in drug development could be made.  
The effect of these inhibitors on pathways related to retinoic acid signalling should also 
be evaluated. qPCR can be used to measure the transcriptional expression of classical and non-
classical RA-pathway target genes following compound treatment, to evaluate the ways in which 
these inhibitors are able to affect RA signalling. For example, ALDH1A1 inhibitors may be able to 
reduce the expression of non-classical targets c-MYC, Cyclin D, and PDK1, verifying the non-
classical RA pathway as a drug target in cancer. Similarly, the activation of pathways that have 
been linked to RA signalling may be evaluated. For example, by collecting cell lysate following 
compound treatment and running a western using a P-AKT antibody, the relative activation of 
the PI3K pathway in treated and non-treated cells can be compared (119). These types of 
experiments would help validate the non-classical RA pathway as a drug target in cancer, and 
help establish CM38 and CM10 analogues as valuable chemical tools in the study of cancer stem 
cell signalling.  
D. Conclusion 
Enzymatic inhibition of ALDH1A enzymes, which are established cancer stem cell 
markers, is a promising, but yet-unexplored avenue to therapeutically target cancer stem cells in 
clinical treatment. The ALDH1A1-selective inhibitor, CM38 and the ALDH1A-selective inhibitor, 
CM10, have been characterized by establishing structure-activity relationships, finding the 
binding modes using X-ray crystallography, and verifying their effectiveness in a cancer cell line. 
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The compounds have helped establish structural features of the ALDH1A1 active site, namely 
the isoenzyme-specific residues Asn121, Gly125, and Gly458, that will be useful in the 
development of additional isoenzyme-selective inhibitors.  The compound series show promise 
as chemical tools to help delineate the roles of ALDH1 isoenzymes in cancer biology and as lead 
compounds in drug development; however, further experiments are needed to verify their in-
cell selectivity and their impact on cancer cell properties and pathways.   
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